NCI Version Date 2/14/12  NCI Protocol #:  NCI 6981 Local Protocol #:  [PHONE_9868]  
Amendment 1: 4/20/05 Disapproved  
Amendment 2: 5/2/05 Disapproved  
Amendment 3: 5/13/05  
Amendment 4: 6/17/05  
Amendment 5: 12/1/05 Disapproved  
Amendment 6: 1/26/06  
Amendment 7: 3/2/06 Disapproved  
Amendm ent 8: 3/17/06  
Amendment 9: 7/14/06  
Amendment 10: 8/31/06  
Amendment 11: 11/29/06  
Amendment 12: 3/7/07  
Amendment 13: 3/27/07  
Amendment 14: 4/27/07  
Amendment 15: 5/29/07  
Amendment 16: 8/18/08 Disapproved  
Amendment 17: 8/26/08  
Amendment 18: 1/7/09 NC I Version Date 1/7/09  
Amendment 19: 5/23/11 NCI Version Date 5/23/11  
Amendment 20: 2/14/12  NCI Version Date 2/14/1 2 
A Phase I/II Trial of BAY [ADDRESS_605274] inating Center:    Montefiore Medical Center  
*Principal Investigator:  [INVESTIGATOR_102603], M.D.  
  Div of Hematology & Medical Oncology  
  [LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]/Cornell  
  [ADDRESS_605275]  
  [LOCATION_001], NY 100 65 
  Tel  [PHONE_9869]  
  Fax  [PHONE_9870]  
  [EMAIL_2014]  
Co-Investigators:    
  David M. Nanus, M.D.  
Div of Hematology & Medical Oncology  
[LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]/Cornell  
[ADDRESS_605276]  
[LOCATION_001], NY 100 65 
Tel [PHONE_9869]  
Fax [PHONE_9870]  
  [EMAIL_9064]  
 
 
 
 
 
NCI Version Date 2/14/12   
  Himisha Beltran, M.D.  
Div of Hematology & Medical Oncology  
[LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]/Cornell  
[ADDRESS_605277]  
[LOCATION_001], NY [ZIP_CODE]  
Tel 646 -962-2072  
Fax 646 -962-1603 
  [EMAIL_9065]  
 
Caryn Ecker, N.P. 
Div of Hematology & Medical Oncology  
[LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]/Cornell  
[ADDRESS_605278]  
[LOCATION_001], NY 100 65 
  Tel  646 -962-2072  
  Fax  646 -962-1603  
[EMAIL_9066]  
 
Daniel Petrylak, M.D.  
Division of Medical Oncology  
[LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]/Columbia  
[ADDRESS_605279]  
[LOCATION_001], NY [ZIP_CODE]  
Tel [PHONE_9871]  
Fax [PHONE_9872]  
[EMAIL_9067]  
 
Thomas Bradley, M.D.  
North Shore University Hospi[INVESTIGATOR_472170]  
[ADDRESS_605280]  
Manhasset, NY [ZIP_CODE]  
Tel [PHONE_9873]  
Fax [PHONE_9874]  
tbrad [EMAIL_9068]  
 
Vincent Vinciguerra, M.D.  
North Shore University Hospi[INVESTIGATOR_472170]  
[ADDRESS_605281]  
Manhasset, N [ZIP_CODE]  
Tel [PHONE_9875]  
Fax [PHONE_9876]  
[EMAIL_9069]  
 
Anna Ferra ri, M.D.  
NCI Version Date 2/14/[ADDRESS_605282]  
[LOCATION_001], NY [ZIP_CODE]  
Tel [PHONE_9877]  
Fax [PHONE_9878]  
[EMAIL_9070]  
 
Joseph Sparano, M.D.  
Montefiore Medical Center  
Department of O ncology  
[ADDRESS_605283]  
Bronx, NY [ZIP_CODE]  
Tel [PHONE_9879]  
Fax [PHONE_9880]  
[EMAIL_9071]  
 
Sanjay Goel, M.D.  
Montefiore Medical Center  
Department of Oncology  
[ADDRESS_605284]  
Bronx, NY 1046 1 
Tel [PHONE_9881]  
Fax [PHONE_9880]  
[EMAIL_9072]  
 
Cy Stein, M.D.  
Montefiore Medical Center  
Department of Oncology  
[ADDRESS_605285]  
Bronx, NY [ZIP_CODE]  
Tel [PHONE_9882]  
Fax [PHONE_9883]  
[EMAIL_9073]  
 
Lakshmi Rajdev, M.D.  
Montefiore Medical Center  
Department of Oncology  
[ADDRESS_605286]  
Bronx, NY [ZIP_CODE]  
Tel [PHONE_9884]  
Fax [PHONE_9880]  
irajdev@montefio re.org  
 
Max Sung, M.D.  
Mount Sinai Medical Center  
One Gustave Levy Place  
[LOCATION_001], NY [ZIP_CODE]  
NCI Version Date 2/14/12  Tel [PHONE_9885]  
Fax [PHONE_6185]  
[EMAIL_9074]  
 
  
Collaborating Radiologist  Krishna Juluru , MD  
   Department of Radi ology  
  Weill Medical College of Cornell University  
  [ADDRESS_605287] , F-056 
  [LOCATION_001], NY [ZIP_CODE]  
  Tel 212 746 -7897  
  [EMAIL_9075]  
  
Statistician :  Madhu Mazumdar , Ph.D.  
Weill Medical College  
Division of Biostatistics and Epi[INVESTIGATOR_623]  
[ADDRESS_605288], Room KB -324A  
[LOCATION_001], NY [ZIP_CODE]  
Tel 212 746 -1460  
Fax 212 746 -8544  
[EMAIL_9076]   
 
Responsible Research  
Nurse:   Gina Mileo , RN  
Div of Hematology & Medical Oncology,  
[LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]  
[ADDRESS_605289]  
Annex Building, Room 811  
[LOCATION_001], NY [ZIP_CODE]  
Tel [PHONE_9886]  
Fax [PHONE_9887]  
gjm2003 @med.cornell.edu  
 
Responsible Data  
Manager:   Ankeeta Saran , BS 
Div of Hematology  & Medical Oncology, Starr [ADDRESS_605290]  
[LOCATION_001], NY [ZIP_CODE]  
Tel [PHONE_9888]  
Fax [PHONE_9889]  
[EMAIL_9077]  
 
NCI Supplied Agent :  BAY 43 -9006 (NSC 724772)  
 
 
 
NCI Version Date 2/14/12  Commercially Supplied Agent:  Gemcitabine  
  Capecitabine  
 
Protocol Version Date:  5/23/11     
NCI Version Date 5/23/11  
 i SCHEMA  
 
 
 
DAY  Week 1  
 
1     2     3     4     5     6     7  Week 2  
 
8     9     10     11     12     13     14  Week 3  
 
15     16     17     18     19     20     21 
Gemcitabine  X X  
Capecitabine  X    X    X    X    X    X    X  X    X     X      X      X      X      X   
BAY 43 -9006  X    X    X    X    X    X    X  X    X     X      X      X      X      X  X       X      X      X       X      X      X  1 Cycle = 21 days  
Gemcitabine:   750 (mg/m2) IV over 30 minutes on days 1 and 8.  
 
Capecitabine:   415 (mg/m2) p.o. twice daily on days 1 -14. 
 
BAY 43 -9006:   200 mg p.o. twice daily will be administered  from day 1 until day 21.  
 
 
Treatment will be continued until disease progression or unacceptable toxicity.  Patients should receive a minimum 
of three cycles of therapy.  Pati ents may discontinue therapy if a complete response is achieved.  
 
 
NCI Version Date 5/23/11  
 ii TABLE OF CON TENTS  
Page  
 
SCHEMA  ................................ ................................ ................................ ................................ ........  i 
 
1. OBJECTIVES  ................................ ................................ ................................ .......................... 2 
 
2. BACKGROUND  ................................ ................................ ................................ ...................... 2 
2.1 Renal Cell Carcinoma  ................................ ................................ ................................ ..2 
2.2 BAY 43 -9006  ................................ ................................ ................................ ................. 2 
2.3 Gemcitabine and Capecitabine  ................................ ................................ ................... 6 
2.4 Rationale  ................................ ................................ ................................ ....................... 7 
 
3. PATIENT SELECTION  ................................ ................................ ................................ ......... 7 
3.1 Eligibility Criteria   ................................ ................................ ................................ .......7 
3.2 Exclusion Criteria  ................................ ................................ ................................ ........ 9 
3.3 Inclusion of Women and M inorities  ................................ ................................ ......... 10 
 
4. PHASE I TREATMENT PLAN  ................................ ................................ ........................... 10 
4.1  BAY 43 -9006, Gemcitabine and Capecitabine  Administration  ............................. 10 
 4.1.1  BAY 43 -9006  ................................ ................................ ................................ ...11 
 4.1.2  Gemcitabine  ................................ ................................ ................................ .....12 
 4.1.3  Capecitabine  ................................ ................................ ................................ .....12 
4.2  Supportive Care Guidelines  ................................ ................................ ...................... 12 
  4.2.1    General Guidelines  ................................ ................................ ........................... 12 
  4.2.2    Palliative Radiation Therapy  ................................ ................................ ............ 12 
  4.2.3    Growth Factors  ................................ ................................ ................................ .12 
  4.2.4    Supportive Management of Hand/Foot Syndrome  ................................ ........... 13 
4.3  Duration of Therapy  ................................ ................................ ................................ ..13 
 
5. PHASE I DOSE LIMITING TOXICITY CRITERIA  ................................ ....................... 14 
 5.1  Definition of Dose Limiting Toxicity  ................................ ................................ ........ 14 
 
6. PHASE II TRIAL  ................................ ................................ ................................ .................. 14 
 6.1  General Guidelines  ................................ ................................ ................................ .....15 
 6.2  Dose Modification Guidelines  ................................ ................................ ................... 15 
 6.3  Treatment -emergent Hypertension  ................................ ................................ .......... 16 
 6.4  Neutropenia/Thrombocytopenia  ................................ ................................ ............... 17 
 6.4.1  Grade 3 Neutropenia/Thrombocytopenia  ................................ ......................... 17 
 6.4.2  Grade 4 Neutropenia/Thrombocytopenia  ................................ ......................... 18 
 6.4.3  Blood Counts on Day 1 of Cycle  ................................ ................................ .....18 
 6.5  Hepatic Dysfunction  ................................ ................................ ................................ ...18 
 6.6  Gastrointestinal Toxicities  ................................ ................................ ......................... 19 
   6.6.1  Grade 2 mucositis and diarrhea  ................................ ................................ ........ 19 
   6.6.2  Grade 3 mucositis and diarrhea  ................................ ................................ ........ 19 
   6.6.3  Grade 4 mucositis and diarrhea  ................................ ................................ ........ 19 
NCI Version Date 5/23/11  
 iii  6.7  Skin Toxicity  ................................ ................................ ................................ ............... 20  
   6.7.1  Grade 2 dermatitis or hand/foot syndrome ................................ ....................... 20 
   6.7.2  Grade 3 dermatitis or hand/foot syndrome ................................ ....................... 20 
   6.7.3  Grade 4 dermatitis  ................................ ................................ ............................ 20  
 6.8  Pulmonary Toxicity  ................................ ................................ ................................ ....21  
 6.9  Unspecified Grade 3 or 4 Toxicities  ................................ ................................ .......... 21 
 6.10 Dose Modification for Obese Patients  ................................ ................................ ......21 
 
7. PHA RMACEUTICAL INFORMATION  ................................ ................................ ............ 21 
7.1  BAY 43 -9006  ................................ ................................ ................................ ............... 21 
7.2  Gemcitabine  ................................ ................................ ................................ ................ 27 
7.3  Capecitabine  ................................ ................................ ................................ ............... 29 
8. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ............... [ADDRESS_605291]  ................................ ................................ .......................... 33 
10.1 Definitions  ................................ ................................ ................................ ................... 33 
10.2 Guidelines for Evaluation of Measurable Disease  ................................ .................. 34 
10.3 Response Criteria  ................................ ................................ ................................ .......35 
10.4 Confirmatory Measurement/Duration of Response  ................................ ............... 37 
10.5 Progression -Free Survival  ................................ ................................ ......................... 38 
10.6 Response Review  ................................ ................................ ................................ ........ 38 
 
11. REGULATORY AND REPORTING REQUIREMENTS  ................................ ................ 38 
11.1 Expedited Adverse Event Reporting  ................................ ................................ ........ 39   
11.1.1  Expedited Reporting Guide lines  ................................ ................................ ......39 
  11.1.2  Expedited Adverse Events Reporting Exclusions  ................................ ............ 41 
 11.1.3  Secondary AML/MDS  ................................ ................................ ..................... 41 
11.2 Data Reporting  ................................ ................................ ................................ ........... 41 
11.3 CTEP Multicenter Guidelines  ................................ ................................ ................... 41 
11.4 Cooperative Research and Development Agreement (CRADA)/  
Clinical Trials Agreement (CTA)  ................................ ................................ ............. 43 
 
12. STATISTICAL CONSIDERATIONS  ................................ ................................ ................. 45 
 
13. REFERENCES  ................................ ................................ ................................ ....................... 47 
APPENDIX A  
Performance Status Criteria  ................................ ................................ ................................ .. A-1 
 
APPENDIX B  
Patient Medication Diary  ................................ ................................ ................................ ...... A-2 
 
APPENDIX C  
Patient Medication Diary for subjects who remain on single -agent sorafenib  .....................   A-3 
 
NCI Version Date 5/23/11  4 1. OBJECTIVES  
 
 1.1. To deter mine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity 
(DLT) of BAY 43 -9006 administered in combination with gemictabine and 
capecitabine in patients with advanced renal cell carcinoma.  
 
1.2. To determine the objective response rate for BAY 43 -9006 in combination with 
gemcitabine and capecitabine in patients with advanced renal cell carcinoma.  
 
1.3. To determine the duration of overall survival and progression free survival in these 
patients.  
 
2. BACKGROUND  
 
2.1  Renal Cell Carcinoma  
 
 Renal Cell  Carcinoma (RCC) accounts for approximately 3% of all malignant adult tumors, 
with an estimated 35,710 new cases and 12,480 RCC related deaths in the year 2004 (1). 
Immunotherapy with interferon alpha or interleukin -2 has become the mainstay of treatment 
with low, but reproducible response rates in the 10% to 15% range and complete responses 
with long term survival in 5% or fewer patients (2).  The only therapy that has been 
demonstrated to improve survival is interferon alpha for which the median survival is 
approximately 2 -3 months (3;4) .  Novel agents are clearly needed in the treatment of patients 
with metastatic RCC.   
 
2.[ADDRESS_605292].  Ras regulates several pathways which synergistically induce 
cellular transformation, including the Raf/Mek/Erk cascade and the rac  and rho 
pathways (5;6) .  In particular, Ras activates the Raf/Mek pathway by [CONTACT_472184], where Raf initiates a mitogenic kinase cascad e.  Activated Raf 
phosphorylates and activates Mek which in turn phosphorylates and activates Erk.  Activated 
Erk then translocates from the cytoplasm into the nucleus and modulates gene expression via 
the phosphorylation of transcription factors.  Thus ac tivation of Raf kinase, via activation of 
Ras, is thought to play an important role in carcinogenesis.  
 
In particular, B -raf, a serine/threonine kinase, has been shown to be activated in a number of 
human tumor types including melanoma, ovarian and papi[INVESTIGATOR_472171] (7-12).  A 
survey of 43 cancer cell lines showed that all B -raf mutations resided in exons 11 or 15.  
Remarkably, 80% of these B -raf mutations represent a single nucleotide change of T -A at 
nucleotide 1796 resulting in a valine to glutamic acid change at r esidue 599 (V599E, exon 
15) in the CR3 domain (ATP binding and substrate recognition) which in turn confers 
constitutive kinase activity (7;8) . 
 
 
NCI Version Date 5/23/11  5 In Vitro Activity  
 
The abil ity of BAY 43 -9006 to inhibit a number of kinases was evaluated (Investigator’s 
Brochure, 2003).  The in vitro  biochemical and cellular profile of BAY 43 -9006 is 
summarized below:  
 
Biochemical Assay  IC50 (µM)  
c-raf b 0.002/0.006  
b-raf  wild -type 0.025  
b-raf V599E mutant  0.038  
VEGFR -2 (human)  0.090  
VEGFR -2 (murine)  0.006  
VEGFR -3 (murine)  0.010  
PDGFR -β (murine)  0.028  
Flt-3 0.058  
c-KIT 0.068  
FGFR -1 0.580  
p38α 0.038  
Cellular Mechanismc IC50 (µM)  
MDA -MB-231 MEK phosphorylation (Human 
Breast)  0.04 
BxPC-3 MEK phosphorylation (Human Pancreatic)  1.00 
LOX ERK phosphorylation (Human Melanoma)  0.80 
b-raf ER MEK activation (Human Chimera, 3T3 
cells)  2.30 
VEGFR -2 phosphorylation (Human, 3T3 cells)  0.03 
VEGFR -3 phosphorylation (Mouse, 293 cells)  0.10 
PDG FR-β phosphorylation (Human, AoSMC)d 0.02 
Cellular Proliferation  IC50 (µM)  
MDA -MB-231 (10% FCS)e 2.60 
MDA -MB-231 (0.1% FCS)  0.10 
VEGF -HUVEC  (2.0% FCS)f 3.00 
PDGFR -β AoSMCd (0.1%  BSA)g 0.23 
a Recombinant enzyme assay  
b Raf kinase activated with Lck ( truncated/full length c -raf) 
c Mechanistic cellular assays all performed in 0.1% BSA  
d Human aortic smooth muscle cells  
e Fetal calf serum  
f  Human umbilical vein endothelial cells  
g Bovine serum albumin  
 
In vitro  kinase assays demonstrated that BAY 43 -9006  is a potent inhibitor of wildtype and 
mutant (V599E) B -Raf and c -Raf Kinase isoforms in vitro   (Investigator’s Brochure, 2003).  
In addition, BAY 43 -9006 did not inhibit human EGFR or Her2 kinases at 10 M.  Nor were 
PKC -α, PKC -β, PKC -γ, and PKA (rat, rabbit and bovine sources) kinase activity inhibited in 
vitro .  BAY [ADDRESS_605293] p59 (bovine) Fyn kinase (Src 
family of protein tyrosine kinases).  In non -kinase targets BAY  43-[ADDRESS_605294] the adenosine A3, dopamine D1, and muscarinic M3 receptors with IC 50 of 
1.6 M, 2.0 M, and 3.1 M, respectively.  BAY 43 -9006 did not inhibit MEK -1, ERK -1, 
EGFR, HER2/neu, c -met, PKA, PKB, Cdk -1/cyclin B, pim -1, [COMPANY_004] 3 -b, CK -2, PKC -α (r), 
PKC -β (r), PKC -γ at concentrations as high as 10 µM.  In summary, BAY 43 -9006 showed 
 
NCI Version Date 5/23/11  6 ≥100 -fold more selectivity for raf kinase relative to other target proteins.  
BAY 43 -9006 also inhibited in vitro  several receptor tyrosine kinases (RT Ks) that are 
involved in tumor progression; human VEGFR -2, murine VEGFR -2, murine VEGFR -3, 
murine PDGFR -β, Flt -3, c-KIT, and p38α (MAPK family).  In cellular assays, BAY 43 -9006  
was found to be a potent inhibitor of human and murine VEGFR -2, murine VEGFR -3, and 
murine PDGFR -β receptor phosphorylation (Investigator’s Brochure, 2003).  
 
VEGF and PDGF receptors are involved in the mechanism of tumor angiogenesis (13;14) .  
PDGF receptors  may also play a role in patients with chronic myeloproliferative cancers (15). 
Flt-3 is important in acute myelogenous leukemia (16) and c -Kit plays a critical role in 
gastrointestinal stromal tumors (17). 
 
In Vivo Activity  
 
BAY [ADDRESS_605295] -116 and DLD -1 colon tumor xenografts, MX -1 mammary tumor 
xenograft, NCI -H460 and A549 NS CLC xenografts, MiaPaCa -2 pancreatic tumor xenografts, 
and SK -OV-3 ovarian tumor xenografts. In this table, compound efficacy is expressed as 
percent tumor growth inhibition (TGI) and is calculated as ((1 -(T/C)) *100, where T and C 
represent the mean tumor  size in the Treated and Control groups respectively at the first 
measurement after the end of treatment.  
 
BAY [ADDRESS_605296] Spectrum Anti -Tumor 
Efficacy in Preclinical Xenograft Models  
 
Tumor Type  Model  Dose (mg/kg/dose free 
base equiv.)1 Percent TGI  
((1-(T/C))*100)  
Colon  HCT -116 10 
30 
100 45 
64 
68 
Colon  DLD -1 15 
30 
60 31 
66 
75 
NSCLC  NCI-H460  10 
30 27 
56 
NSCLC  A549  30 
60 60 
68 
Mammary  MX-1 30 
60 51 
67 
Pancreatic  Mia-PaCa -2 10 
30 
100 45 
66 
73 
Ovarian  SK-OV-3 10 
30 
100 58 
64 
81 
 
NCI Version Date 5/23/[ADDRESS_605297] two additional human tumor 
xenograft models that contain K -ras mutations: MiaPaCa -[ADDRESS_605298] the human SKOV -3 ovarian tumor cell line that contains a wild -type Ras but over -
expresses both the EGF and Her2 growth factor receptors.  These receptors also signal 
through the Ras/Raf/ Mek pathway.  
 
In human tumor xenografts, MDA -MB-231 (breast) and Colo -205 (colon), there was a 
dramatic reduction of tumor neo -vascularization (Investigator’s Brochure, 2003).  Recent 
data also indicated that inhibition of c -raf may promote cell death in e ndothelial cells as a 
downstream event of VEGFR -2 stimulation (18). 
 
Taken togethe r, data suggests that BAY 43 -9006 may be of therapeutic value not only in 
human tumors containing ras gene mutations, but also in tumors over -expressing growth 
factor receptors in the Ras/Raf/Mek pathway, and by [CONTACT_298829] -
vascula rization through inhibit ion of VEGFR -2, VEGFR -3, and/or PDGFR -β. 
 
The ability of BAY 43 -9006 (or its tosylate salt, BAY 54 -9085) to be combined with 
paclitaxel, irinotecan, gemcitabine, or cisplatin was evaluated in preclinical in vivo  models.  
In these studies, the focus was to evaluate if the co -administration of BAY [ADDRESS_605299] the tolerance or anti -tumor efficacy of the ‘standard of care’ agent. The 
general health of mice was monitored and mortality was recorded daily. Tumor dimensions 
and body weights were recorded twice a week starting with the first day of treatment. 
Treatments producing greater than 20% lethality and/or 20% net body weight loss were 
considered ‘toxic’.  The results of these combinability analyses are summarized below:  
 
Combinability of Co ncurrent Treatment with BAY 43 -9006 and  
Clinically Established Agents  
 
Combination 
Agent  Tumor Model  Combinability  
Y/N 
Paclitaxel  NCI-H460 NSCLC  
MX-1 Mammary  Yes 
Yes 
Irinotecan  DLD -1 Colon               Yes 
Gemcitabine  MiaPaCa -2 Pancreatic  Yes 
Cisplatin  NCI-H23 NSCLC  Yes 
 
NCI Version Date 5/23/[ADDRESS_605300] been tested: continuous treatment, 
4 weeks on/ 1 week off, 3 weeks on /1 week off, and 1 week on/ [ADDRESS_605301] 
received doses ranging from 50 mg once weekly to 1600 mg daily of BAY 43 -9006 on 
intermittent and continuous schedules.  The 800 mg bid continuous administration cohort has 
exceeded maximum tolerated dose (MTD) in all tested schedules. The 600 mg bid cohort 
exceeded the MTD in all but the less dose in tensive regimen of 1 week on / [ADDRESS_605302] frequent drug -related adverse events were hand -foot skin reaction, dermatitis, rash, 
fatigue, anorexia and diarrhea.  There was an increase in the number of serious adverse 
events, discontinuations due t o adverse eve nts, and a number of skin toxicities at the higher 
dose levels ≥ [ADDRESS_605303] frequent drug -related toxicities observed 
include hand -foot skin reacti on, rash, anorexia, diarrhea, and fatigue. When all available data 
from the various studies/schedules are combined, the incidence of greater than grade 3 
treatment emergent skin toxicity (e.g. hand -foot syndrome and “dermatology/skin reaction”) 
for an init ial dose of 400 mg bid and 600 mg bid, was 0% and 30%, respectively. Anti -tumor 
activity was observed in both Phase 1 and 2 studies.  
 
2.3  Gemcitabine and Capecitabine  
 
Historically, chemotherapy has been ineffective in the treatment of RCC (19), however, recent 
trials using gemcitabine in combination with 5 -fluorouracil (5 -FU) or capecitabin e have 
demonstrated response rates as high as 21% (20;21;27) .  The Cancer and Leukemia Group B 
recently completed a phase II study (#[ZIP_CODE]) of gemcitabine and capecitabi ne in patients with 
metastatic RCC(27).  Patients were treated with gemcitabine at 1000 mg/m2 day 1, 8, 15 and 
 
NCI Version Date 5/23/11  9 capecitabine at 830 mg/m2 twice daily, days 1 -21 on a 28 day cycle.  Partial responses were 
observed in 8 out of 55 patients for a response rate of 15% with a median duration of 
response and time to progression of 7.1 and 5.1 months, respectively.  Grade 3,4 toxicities 
included neutropenia (40%) with febrile neutropenia in 1 patient, anemia (15%), 
thrombocytopenia (6%), nausea (11%), fatigue (7%), diarrhea (7%), and hand/foot syndrome 
and stomatitis (2% each).  Grade 1, 2 toxicities included leukopenia (49%), fatigue (62%), 
nausea (42%), stomatitis (29%), diarrhea (27%), and hand/foot syndrome (36%).  The 
investigators concluded that the combination  of gemcitabine and capecitabine has modest 
activity in metastatic RCC, however, further evaluation of the regimen would require a dose 
modification.  An evaluation of prognostic factors for survival with gemcitabine plus [ADDRESS_605304] chemotherapy approaches (22).   
 
2.[ADDRESS_605305] separately been evaluated in combination with BAY 
43-9006.  A phase I/II trial of BAY 43 -9006 and gemcitabine in patients with advanced solid 
tumors and in advanced pancreatic cancer revealed a lack of pharmacokinetic interaction 
between the two and non -overlappi[INVESTIGATOR_472172] (23).  A single -center phase I study of 
BAY 43 -9006 in combination with capecitabine (Bayer Pharmaceuti cals).  BAY 43 -9006 was 
administered orally (bid) from day 8 until day 21 in cycle 1, and continuously thereafter in 
doses of: 200 mg bid (Cohort 1), 400 mg bid (Cohort 2), and (for Cohort 3 only) [ADDRESS_605306] two cycles, then 400 mg bid for ea ch subsequent cycle.  Capecitabine was given 
orally bid (2100 mg/m2 per day) from day 1 in a 2 weeks on/[ADDRESS_605307] 
frequent drug -related toxicities were hand/foot syndrome, diarrhea, fatigue, mucositis, and 
nausea.  Dose -limiting toxici ties included grade 3 hand/foot syndrome and grade 3 diarrhea in 
Cohort 1, and grade 3 hand/foot syndrome and grade 3 mucositis in Cohort 2.  Treatment is 
ongoing in Cohort 3.  An additional cohort has been added to evaluate BAY 43 -9006 400 mg 
bid and cape citabine 1700 mg/m2 per day.  Preliminary pharmacokinetic analysis of BAY [ADDRESS_605308] histologically or cytologically confirmed renal cell 
carcinoma that is unresectable and/or metastatic.  Patients with collect ing duct 
carcinoma, oncocytomas, or transitional cell carcinoma are not eligible.  
Patients with sarcomatoid renal cell carcinoma are eligible, but those with 
pure sarcomas are not.  Histologic documentation of metastatic disease is not 
required.  Clinical  confirmation, but not pathologic staging, of metastatic 
disease is required.  
 
NCI Version Date 5/23/[ADDRESS_605309] one dimension (longest diameter to be 
recorded) as >20 mm with conventional techniques or as >[ADDRESS_605310] received one prior immunotherapy based regimen (i.e. 
interleukin -2 or interferon alpha) ending ≥ [ADDRESS_605311] inhibitor s (e.g. sunitinib or bevacizumab) and/or mTOR inhibitor 
(e.g. temsirolimus) ending > 4 weeks prior to enrollment.  
 
3.1.5  Age >18 years.  Because no  dosing or adverse event data are currently 
available on the use of BAY 43 -9006 in combination with gemcitabine and 
capecitabine in patients < 18 years of age, children are excluded from this 
study but will be eligible for future pediatric phase 2 combinat ion trials.  
 
3.1.6  Life expectancy of greater than 3 months (assessed using MSKCC Criteria , J 
Clin Oncol 20:289 -96, 2002).  
 
3.1.7  ECOG performance status <2 (Karnofsky >60%; see Appendix A).  
 
3.1.[ADDRESS_605312] normal organ and marrow function as def ined below:  
 
- leukocytes       >3,000/L 
- absolute neutrophil count   >1,500/L 
- platelets       >100,000/L 
- total bilirubin      <1.[ADDRESS_605313](SGOT)/ALT(SGPT)   <2.5 X institutional upper limit of normal  
- creatinine       <1.5 X institutional upper limit of normal  
OR 
- creatinine clearance    >60 mL/min/1.[ADDRESS_605314] 
agree to use adequate contraception (hormonal or barrier method of birth 
control; abstinence)  prior to study entry and for the duration of study 
participation.  Should a woman become pregnant or suspect she is pregnant 
while participating in this study, she should inform her treating physician 
immediately.  
 
3.1.10  Ability to understand and the wil lingness to sign a written informed consent 
document.  
 
NCI Version Date 5/23/[ADDRESS_605315] 8 
weeks after completion of surgery and/or radiotherapy  
 
3.2.4  History of allergic reactions attributed to compounds of similar chemical or 
biologic composition to BAY 43 -9006, gemcitabine and capecitabine.  
 
3.2.5  No concurrent megestrol is permitted .  No megestrol therapy within 4 weeks 
prior to protocol treatment is allowed.  No concurrent cytochrome P450 
enzyme -inducing antiepi[INVESTIGATOR_006] (phenytoin, phenobarbitol or 
carba mazepi[INVESTIGATOR_050]), rifampin, or St. John’s wort.  
 
3.2.6  Uncontrolled intercurrent illness including, but not limited to, uncontrolled 
hypertension, ongoing or active infection, symptomatic congestive heart 
failure, unstable angina pectoris, cardiac arrhythmia, pul monary disease 
including asthma, chronic bronchitis, emphysema with requirements for 
chronic oxygen use or psychiatric illness/social situations that would limit 
compliance with study requirements.  
 
3.2.7 Pregnant women are excluded from this study because BAY 4 3-9006 is a 
kinase inhibitor  agent with the potential for teratogenic or abortifacient effects. 
Because there is an unknown but potential risk for adverse events in nursing 
infants secondary to treatment of the mother with BAY 43 -9006, breastfeeding 
should  be discontinued if the mother is treated with  BAY 43 -9006.  The 
potential risks may apply to other agents used in this study.  
 
3.2.8 Because patients with immune deficiency are at increased risk of lethal 
infections when treated with marrow -suppressive therapy , HIV -positive 
patients receiving combination anti -retroviral therapy are excluded from the 
study because of possible pharmacokinetic interactions with BAY 43 -9006, 
 
NCI Version Date 5/23/11  12 gemcitabine, or capecitabine administered during the study.  Appropriate 
studies will be un dertaken in patients receiving combination ant -retroviral 
therapy when indicated.  
 
3.2.9 Any swallowing dysfunction leading to difficulty taking the investigational 
therapy or capecitabine.  
 
3.2.10  Prior treatment with BAY 43 -9006 (sorafenib).  
 
3.2.11  Patients with any histor y or evidence of a bleeding diathesis.  
 
3.2.12  Patients on therapeutic anticoagulation  with coumarins (e.g. warfarin).   
Prophylactic coumarin -based anticoagulation (i.e. low dose warfarin) for 
venous or arterial access devices is allowed provided that the require ments for 
PT, INR and/or PTT are met.  Prophylactic or therapeutic low molecular 
weight heparin is allowed. Patients with known brain metastases are excluded 
(even if treated and stable) if they are also on therapeutic doses of 
anticoagulation.  
 
3.2.13  Patients wi th known dihydropyrimidine dehydrogenase deficiency.  
 
3.3  Inclusion of Women and Minorities  
 
Both men and women and members of all races and ethnic groups are eligible for this 
trial.  
 
4. PHASE I TREATMENT PLAN  
 
4.1  BAY 43 -9006, Gemcitabine and Capecit abine  Administration  
 
Treatment will be administered on an  outpatient basis.  Reported adverse events and 
potential risks for BAY 43 -9006, gemcitabine and capecitabine are described in 
Section 7.  Appropriate dose modifications for BAY 43 -9006, gemcitabine  and 
capecitabine are described in Section 6.  No investigational or commercial agents or 
therapi[INVESTIGATOR_378295]’s malignancy.  
 
The phase I dose escalation study will be conducted  according to the dosing regimen 
described in the table below.   
 
Cohort  BAY 43 -9006  Gemcitabine Capecitabine 
A 200 mg p.o. bid x 21d  750 mg/m2 IV d1 & 8  415 mg/m2 p.o. bid x 14d  
B 400 mg p.o. bid x 21d  750 mg/m2 IV d1 & 8  415 mg/m2 p.o. bid x 14d  
C 400 mg p.o. bid x 21d  1000 mg/m2 IV d1 & 8  415 mg/m2 p.o. bid x 14d  
D 400 mg p.o. bid x 21d  1000 mg/m2 IV d1 & 8  622 mg/m2 p.o. bid x 14d  
 
 
NCI Version Date 5/23/[ADDRESS_605316] 
completed day 21 of cycle 2 without experiencing a dose limiting toxicity (DLT) as 
defined in Section 5.  A cycle is defined as a 21 -day period starting with the 
administration of BAY 43 -9006, gemc itabine and c apecitabine on day 1.   
 
If a DLT is observed in 1  of 3 subjects, then a total of 6 subjects will complete 2 
cycles prior to opening the next cohort.  If <  2 of the 6 subjects experience a DLT, 
dose escalation can continue.  However, if ≥  2 of 6 subjects e xperience a DLT, then 
the maximum tolerated dose (MTD) has been exceeded.  The MTD is generally one 
dose below that at which DLT occurs in > [ADDRESS_605317] of a minimum of 3 s ubjects and a 
maximum of 6 subjects excluding the MTD or similar cohort.   
 
Patients should receive a minimum of three 21 -day cycles of treatment.  Responding 
patients or those with stable disease may continue to receive treatment until disease 
progression .  
 
Patients with an objective response or stable disease, who at the discretion of the 
Principal Investigator, are unable to continue chemotherapy or patients meeting dose 
modification criteria for stoppi[INVESTIGATOR_472173] 6 may receive  
BAY 43 -9006 alone until disease progression.  
 
After establishing the MTD of BAY 43 -9006 in combination with gemcitabine and 
capecitabine in the phase I trial, an additional 12 to 35 patients will be treated at the 
MTD regimen.  
 
4.1.1  BAY 43 -9006  
 
 BAY 43 -9006 is supplied as 200 -mg tablets and is administered orally. 
Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of 
water, each morning and evening (i.e., 12 -hourly). BAY 43 -9006 is to be 
taken on an empty stomach (at least [ADDRESS_605318] the blood pressure 
measureme nts in their doctor’s office, a clinic or using a calibrated machine 
such as can be found at a supermarket or shoppi[INVESTIGATOR_404098].  Patients should 
record their blood pressure measurements and if they are in the normal range,  
bring the measurements to the clini c at the time of routine follow -up.  If blood 
pressure readings are abnormal (e.g. >150/100) then patients should contact 
 
[CONTACT_472185] 5/23/11  14 their doctor promptly.  
 
 
 
4.1.2  Gemcitabine  
 
Gemcitabine will be administered intravenously over 30 minutes on days 1 
and 8.  
 
  4.1.3  Capecitabine  
 
The capecitabine dose is given orally in two divided doses (approximately 12 
hours apart) at the end of a meal.  The tablets should be swallowed with water. 
Patients who take aluminum hydroxide - or magnesium hydroxide - containing 
antacids sh ould be instructed not to take them within one hour of capecitabine 
administration.  Capecitabine will be administered p.o. bid from days [ADDRESS_605319] period.  
 
Patients will maintain a medication log to monitor compliance wi th BAY 43 -9006 
and capecitabine.  The medication diary should be signed and dated by [CONTACT_264029]/or person who completes the diary so that it may serve as source documentation 
of treatment administration.  A copy of the medication diary is included as Appendix 
B. 
 
4.2  Supportive Care Guidelines  
   
4.2.1  General Guidelines  
 
Institutional guidelines and the discretion of the treating physician should be 
used for decisions regarding transfusions of blood and blood products, 
erythropoietin (EPO), antibioti cs, and antiemetics.   
 
Chemotherapy induced diarrhea should be managed as per ASCO guidelines.  
 
4.2.2  Palliative Radiation Therapy  
 
Palliative radiation therapy may not be administered while patient is on the 
protocol.  The need for palliative radiation i ndicates progressive disease and 
the patient should be removed from the protocol treatment.  Irradiate any 
lesion that may produce disability (e.g., unstable femur) prior to study 
initiation.  
 
4.2.3  Growth Factors  
 
Filgrastim (G -CSF) and sargramostim (GM -CSF) may NOT be used:  
 
 
NCI Version Date 5/23/11  15 a. to avoid dose reductions, delays or to allow for dose escalations specified 
in the protocol.  
 
b. prophylactically because of concern about myelosuppression from prior 
therapi[INVESTIGATOR_014].  
For the treatment of febrile neutropenia the use of CSF’s s hould not be 
routinely instituted as an adjunct to appropriate antibiotic therapy.  However, 
the use of CSF’s may be indicated in patients who have prognostic factors that 
are predictive of clinical deterioration such as pneumonia, hypotension, multi -
organ  dysfunction (sepsis syndrome) or fungal infection, as per the ASCO 
guidelines.  Investigators should therefore use their own discretion in using the 
CSF’s in this setting.  The use of CSF (filgrastim and sargramostim) must be 
documented and reported on fl ow sheets.  
 
 4.2.4  Supportive Management of Hand/Foot Syndrome  
 
Patients who develop hand/foot syndrome may receive topi[INVESTIGATOR_39669] 
(such as Aquaphor) as well as topi[INVESTIGATOR_472174].  Vitamin B6 (pyridoxine 50 -150 mg orally daily) may also be 
used.  
 
4.3  Duration of Therapy  
 
Patients should receive a minimum of 3 cycles of therapy.  Patients may discontinue 
protocol therapy if a complete response is achieved.   
 
In the absence of treatment delays due to adverse events,  treatment may continue until 
one of the following criteria applies:  
 
 Disease progression,  
 Intercurrent illness that prevents further administration of treatment,  
 Unacceptable adverse events(s),  
 Patient decides to withdraw from the study, or  
 General or spe cific changes in the patient's condition render the patient 
unacceptable for further treatment in the judgment of the investigator.  
 
  Subjects who complete at least 3 cycles of treatment  with objective response or stable 
disease  who are deemed poor candid ates for continued chemotherapy may continue 
therapy with BAY 43 -9006 at their current dose.  The dose of BAY 43 -9006 may be 
escalated at the discretion of the investigator after 3 weeks at the current dose up to a 
maximum of 400 mg BID.  Subjects who cont inue on BAY 43 -9006 alone will 
continue with weekly follow up until resolution of toxicities attributable to 
chemotherapy (gemcitabine and capecitabine) to < Gr 1.  Following resolution of 
chemotherapy -atributable toxicities to < Gr 1, investigators may el ect to lengthen the 
interval between  study visits to a maximum of 4 weeks  provided that study drug -
attributable non -hematologic toxicities are stable at Gr <1. Other study procedures 
 
NCI Version Date 5/23/[ADDRESS_605320] 12 cycles and non -hematologic toxicities stable at Gr <1, study procedures may 
be performed every 4 weeks.  Radiographic evaluation should continue every 3 cycles 
(i.e. for those stable on 4 -week cycles, scan should be performed every 12  weeks).  
 
   
  All patients who receive at least one cycle of treatment will be followed until disease 
progression, or for a maximum of [ADDRESS_605321] and/or the referring physician  or via medical record review.  
 
5. PHASE I DOSE LIMITING TOXICITY CRITERIA  
 
The current version (3.0) of the NCI Co mmon Terminology Criteria for Adverse Events 
will be used to grade toxicity ( http://ctep.info.nih.gov/ ). 
 
5.[ADDRESS_605322] two 
cycles of therapy:  
 
1. Treatment Emergent Hypertension as follows:  
a. Any Grade 2 symptomatic/persistant (requiring a treatment delay for > 2 
weeks)  
b. Diastolic BP  110 mm Hg  
c. Any Grade 3 or 4  
2. Any Grade 3 or 4 dermatitis or hand/foot s yndrome.  
3. Any Grade 3 neutropenia or thrombocytopenia.  
4. Any Grade 4 neutropenia or thrombocytopenia consisting of:  
a. Febrile neutropenia (defined as temperature ≥ 38.5°C [101°F] sustained 
for more than one hour concomitant with an ANC < 500/mm3) 
b. granulocytes <  500/µl  
c. platelets < 10,000/µl  
5. Any non -hematologic Grade 3 or 4 toxicity “possibly” or “probably related” to 
one of, or the combination of the study drugs being evaluated.  
 
  At the discretion of the Principal Investigator, patients experiencing DLT may  
continue to receive treatment using the Phase II dose modifications as defined in 
Section 6.  
 
6.  PHASE II TRIAL  
 
After establishing the MTD of BAY 43 -9006 in combination with gemcitabine and 
capecitabine in the phase I trial, an additional 12 to 35 patients  will be treated at the MTD 
 
NCI Version Date 5/23/11  17 regimen.    
 
 
 
 
 
The MTD has been determined in the phase I portion of the trial:  
 
BAY 43 -9006 200 mg p.o. BID D1 -D21 
Gemcitabine 750 mg/m2 IV D1, D8  
Capecitabine 415 mg/m2 p.o. BID D1 -D14 
 
General guidelines and dose modificati ons for the combination are outlined below:  
 
 6.1 General Guidelines  
                   
                  Depending on the type of toxicity, a cycle interrupted may either not be completed or 
may continue with dose/treatment modification as defined through out Section 6  
below. A new cycle may begin as soon as all laboratory eligibility criteria are met (see 
Section 3.1.7) and all other toxicity has resolved to baseline or at least grade 1, as 
long as at least one and not more than three weeks have elapsed si nce therapy was 
interrupted i.e. a delay of > 3 weeks in the re -initiation of therapy will result in the 
removal of the patient from the protocol treatment.  
 
Doses will not be re -escalated.  
 
6.2  Dose Modification Guidelines   
 
Dose modification for BAY 43 -9006, gemcitabine and capecitabine will occur as 
illustrated in the tables below. Due to differences in the toxicity profiles of the 
individual agents, dose modification may occur for one drug only (section 6.4).  
 
BAY 43 -9006 dose modifications will take p lace according to the table below:  
 
Dose Level  BAY 43 -9006  
0 200 mg BID 
-1 50% reduction ( 200 mg 
daily)  
-[ADDRESS_605323] according to the table below:  
 
Dose Level  Gemcitabine  
0 750 mg/m2 
-1 25% re duction (563 
mg/m2) 
 
NCI Version Date 5/23/11  18 -2 50% reduction (375 
mg/m2) 
-[ADDRESS_605324] according to the table below:  
 
Dose Level  Capecitabine  
0 415 mg/m2  
-1 25% dose reduction 
-2 STOP CAPECITABINE  
Capecitabine is avai lable in two tablet sizes, 500 mg (peach colored) and 150 
mg (light peach colored).  The following tables display the total daily dose by 
[CONTACT_472186].  
 
Capecitabine Dose Calculation According to Body  Surface Area  
                         
                              Capecitabine Dose Level 0 -1 
 
415 mg/m2 bid Number of tablets to be taken at each dose 
(morning and evening)  
Surface area (m2) Total Daily Dose (mg)  150 mg  500 mg  
≤ 1.29  1000 0 1 
1.30-1.47 1000 0 1 
1.48-1.68 1300 1 1 
1.69-1.89 1600 2 1 
1.90-2.07 1600 2 1 
2.08-2.28 1900 3 1 
≥ 2.29  2000 0 2 
 
                              Capecitabine Dose Level 1 -2 
 
311 mg/m2 bid Number of tablets to be taken at each dose 
(morning and evening)  
Surfa ce area (m2) Total Daily Dose (mg)  150 mg  500 mg  
≤ 1.29  900 3 0 
1.30-1.47 900 3 0 
1.48-1.68 1000 0 1 
1.69-1.89 1000 0 1 
1.90-2.07 1200 4 0 
2.08-2.28 1300 1 1 
≥ 2.29  1600 2 1 
 
6.3  Treatment -emergent Hypertension  
 
NCI Version Date 5/23/[ADDRESS_605325] 4 weeks.  
 
Dose modification for BAY 43 -9006 will occur for treatment -emergent hypertension 
as outlined in the table below:  
                   Management of Treatment -emergent Hypertension  
 
 
Current CTCAE definitions used by [CONTACT_472]:  
Grade 1 :  asymptomatic, transient (< 24 hours) increase by > 20 mmHg (diastolic) or to  
                      >150/100 if previously WNL; intervention not indicated  
Grade 2:  recurrent or persistent (> 24 hours) or symptomatic increase by > 20 mmHg        
          (diastolic) or to > 150/100 if previously WNL; monotherapy may be indicated  
Grade 3:  requiring more than one drug or more intensive therapy than previously  
Grade 4:  life threatening (e.g. hypertensive crisis)  
 
6.4  Neutropenia/Thrombocytopenia  
 
6.4.1  Grade 3 Neutropenia/Thrombocytopenia  
 
    If grade 3 neutropenia or thrombocytopenia develops in any cycle, all therapy 
should be held with the exception of BAY 43 -9006, which may be continued 
at 200 mg p.o. b.i.d or at current dose.  
 
    Therapy should be  reinitiated as a new cycle according to the guidelines 
outlined in Section 6.1. Capecitabine should be decreased by 1 dose level, but 
gemcitabine can be resumed at the previous dose. If capecitabine has already 
been discontinued and a patient experiences grade 3 or 4 neutropenia or 
thrombocytopenia on Day 8 of any given cycle, gemcitabine should be Grade of Event (CTCAE v.3)  Management/ Next Dose  
grade 1  Consider increased BP monitoring  
grade 2 asymptomatic and 
diastolic BP < 110 mm Hg  Begin anti -hypertensive therapy and continue 
agent  
grade 2 symptomatic/ persistent  
OR 
diastolic BP ≥ 110 mm Hg  
OR 
grade 3  1. Agent should be held* until symptoms resolve  
    and diastolic BP  ≤ 100 mm Hg; also  
    treat patient with anti -hypertensives and when  
    agent is restarted, reduce by 1 dose level.**  
2. If diastolic BP not contro lled (≤ 100) on  
    therapy, reduce another dose level ***  
grade 4  Discontinue protocol therapy  
  * Patients requiring a delay of > 2 weeks should go off protocol therapy.  
** May be able to resume full dose later.  
      *** Patients requiring > 2 dose r eductions should go off protocol therapy.  Patients who experience 
treatment -emergent hypertension while receiving BAY 43 -9006 200 mg b.i.d. and require > 1 dose reduction 
should go off protocol therapy.   
 
 
NCI Version Date 5/23/11  20 reduced by 50% for that dose. A full dose of gemcitabine should be resumed 
with the next cycle. If grade 3 neutropenia or thrombocytopenia reoccurs, a 
permanent  dose-reduction of 25% should be made. In the event that 
capecitabine must be stopped, at the discretion of the Principal Investigator, 
patients may continue to receive gemcitabine alone with BAY [ADDRESS_605326] be stopped, 
patients may continue on with BAY 43 -9006 alone at the discretion of the 
Principal Investigator.  
 
6.4.2  Grade 4 Neutropenia/Thrombocytopenia  
   
  Grade 4 neutropenia or thrombocytopenia includes:  
 
• Febrile neutropenia (defined a s temperature ≥ 38.5°C [101°F] 
sustained for more than one hour concomitant with an ANC < 
500/mm3), 
 
• granulocytes < 500/µl, or  
 
• platelets < 10,000/µl  
    
If grade 4 neutropenia or thrombocytopenia develops in any given cycle, all 
therapy should be held wit h the exception of BAY 43 -9006, which may be 
continued at current dose. When therapy is reinitiated according to the 
guidelines in Section 6.1, the dose of gemcitabine should  remain the same 
and capecitabine should be decreased by 1 dose level.  If capeci tabine has 
already been discontinued and a patient experiences grade 3 or 4 neutropenia 
or thrombocytopenia on Day 8 of any given cycle, gemcitabine should be 
reduced by 50% for that dose. A full dose of gemcitabine should be resumed 
with the next cycle. I f grade 3 or 4 neutropenia or thrombocytopenia reoccurs, 
a permanent dose -reduction of 25% should be made. In the event that 
capecitabine must be stopped, at the discretion of the Principal Investigator, 
patients may continue to receive gemcitabine alone w ith BAY [ADDRESS_605327] be met before 
beginning a new cycle (ANC ≥ 1,500/µl, platelets ≥ 100,000/µl).  A delay of > 
3 weeks in the re -initiation of therapy will result in the removal of the patient 
from the protocol treatment.  
 
6.5  Hepatic Dysfunction  
If grade 3 hepatic toxicity develops in any given cycle, gemcitabine, capecitabine and 
 
NCI Version Date 5/23/11  21 BAY 43 -9006 should be held and that cycle of therapy considered complete.  If 
therapy is reinitiated according to the guidelines in Section 6.1 (i.e . all laboratory 
eligibility criteria are met), the dose of gemcitabine should be decreased by 2 dose 
levels.  If grade 3 hepatic toxicity occurs on a subsequent cycle despi[INVESTIGATOR_472175] a 2 dose level reduction would lead to a dose less t han Dose Level -2, 
the patient should be removed from protocol treatment.   
A delay of > [ADDRESS_605328] 
should be decreased by 1 dose level.  If dose reduction of capecitabine would 
lead to a dose less tha n Dose Level -1, at the discretion of the Principal 
Investigator, patients may continue to receive gemcitabine alone with BAY 
43-9006 until disease progression.    A delay of > 3 weeks in the re -initiation of 
therapy will result in the removal of the patien t from the protocol treatment.  
 
6.6.2  Grade 3 mucositis and diarrhea  
 
If grade 3 mucositis or diarrhea develops in a given cycle, all therapy should 
be held and that cycle of therapy considered complete.  When therapy is 
reinitiated according to the guidel ines in Section 6.1, the dose of capecitabine 
should be decreased by 1 dose level.  BAY 43 -9006 and gemcitabine may be 
resumed without dose modification.  If grade 3 mucositis or diarrhea occurs on 
a subsequent cycle despi[INVESTIGATOR_472176] a d ose level reduction of 
capecitabine would lead to a dose less than Dose Level -1, at the discretion of 
the Principal Investigator, patients may continue to receive gemcitabine alone 
with BAY 43 -9006 until disease progression.  A delay of > 3 weeks in the re -
initiation of therapy will result in the removal of the patient from the protocol 
treatment.   
   
6.6.3  Grade 4 mucositis and diarrhea  
 
If grade 4 mucositis or diarrhea develops in a given cycle, all therapy should 
be held and that cycle of therapy consid ered complete.  Capecitabine should 
be stopped and at  the discretion of the Principal Investigator, patients may 
continue to receive gemcitabine alone with BAY 43 -9006 until disease 
 
NCI Version Date 5/23/11  22 progression.  A delay of > 3 weeks in the re -initiation of therapy will res ult in 
the removal of the patient from the protocol treatment.     
 
 6.6.4 GI Perforation (NOS)  
 
If GI perforation occurs, the patient must be taken off therapy completely.  
6.7 Skin Toxicity  
 
 The following table should be used for grading hand/foot syndro me: 
  
Grade  Clinical Domain  Functional Domain  
1 Numbness, dysesthesia/paresthesia, 
tingling, or painless swelling or 
erythema  Discomfort which does not disrupt 
normal activities  
[ADDRESS_605329] important intensity from one domain or the other.  
 
6.7.1  Grade 2 dermatitis or hand/foot syndrome  
 
If grade 2 dermatitis or hand/foot syndrome develops in a given cycle, BAY 
43-[ADDRESS_605330] be stopped, at the discretion 
of the Principal Investigator, patients may continue to receive BAY 43 -9006 
with gemcitabine until disease progression.   A delay of > 3 weeks in the re -
initiation of therapy will result in the removal of the patient from the protocol 
treatment  
 
6.7.2  Grade 3 dermatitis or hand/foot syndrome  
 
If grade 3 dermatitis or hand/foot syndrome develops in a given cycle, all 
therapy should be held and that cycle of therapy considered complete.  When 
therapy is reinitiated according to the guidelines in Section 6.1, the dose of   
capecitabine should be decreased by [ADDRESS_605331] be stopped, at the discretion of the Principal Investigator, 
patients may continue to receive BAY 43 -9006 with gemcitabine until disease 
progression.   A delay of > 3 weeks in the re -initiation of therapy will result in 
the removal of the patient from the protocol treatment  
 
6.7.3  Grade 4 dermatitis  
 
 
NCI Version Date 5/23/11  23 If grade 4 dermatitis develops, the patient should be removed from protocol 
treatment.  
 
 
 
 
6.8 Pulmonary Toxicity  
 
If a patient develops gemcitabine -induced pulmonary toxicity with  Grade 3 
dyspnea, gemcitabine should be discontinued and further protocol therapy terminated. 
      
6.9 Unspecified Grade 3 or 4  Toxicities  
 
For any other grade 3 or 4 non -hematologic, drug -related toxicity not listed in 
Sections 6.2 - 6.8, except for alopecia and isolated anemia, all therapy should be held 
and that cycle of therapy considered complete.  When therapy is reinitiated according 
to the guidelines in Section 6.1, the doses of BAY 43 -9006, gemcitabine and 
capecitabine should be decreased by 1 dose level.  If the same grade 3 or 4 toxicity 
occurs on a subsequent cycle despi[INVESTIGATOR_472176] a dose level reducti on 
of any agent would lead to a dose less than  Dose Level –1 for BAY 43 -9006 . Dose 
Level -2 for  gemcitabine or Dose Level –1 for capecitabine, the patient should be 
removed from protocol treatment.  A delay of > 3 weeks in the re -initiation of therapy 
will result in the removal of the patient from the protocol treatment  
 
6.10 Dose Modification for Obese Patients  
 
There will be no dose modification for obese patients.  All dosing is to be determined 
solely by (1) the patient’s BSA as calculated from actual w eight or (2) actual weight 
without modification unless explicitly described in the protocol.   
  
7. PHARMACEUTICAL INFORMATION  
 
 7.1  BAY 43 -9006 (NSC 724772)  
 
Chemical Name:  4–{4-[3-(4-chloro -3-trifluoromethyl -phenyl) ureido] -phenoxy} -pyridine -2 
carboxyl ic acid methylamide -4-methylbenzensulfonate.  
 
Other Names:   BAY 54 -9085 is the tosylate salt of BAY 43 -9006; sorafenib  
 
Classification:   Kinase inhibitor (Raf, VEGF -R, and PDGF -R) 
 
Mechanism of Action:  The ras/raf signaling pathway is an important mediator  of responses to 
growth signals and angiogenic factors. This pathway is often aberrantly 
activated in human tumors due to presence of activated ras, mutant b -
raf, or over expression of growth factor receptors.  
 
 
NCI Version Date 5/23/11  24 BAY 43 -9006 is a potent inhibitor of c -raf, and wild -type and mutant b -
raf in vitro. Additionally, further characterization of BAY 43 -9006 
tosylate revealed that this agent inhibits several receptor tyrosine 
kinases (RTKs) that are involved in tumor progression (VEGF -R, 
PDGF -R, Flt3, and c -KIT) and p38α, a member of the MAPK family.  
 
Molecular Formula:  C12H16CIF 3N4O3 X C 7H8O3S  
 
M.W.:   BAY 43 -9006 tosylate:  637 Daltons; BAY 43 -9006 (free base): 465 Daltons  
 
Approximate Solubility:   0.19 mg/100 mL in 0.1 N HCl, 453 mg/100 mL in Ethanol, and 2971 
mg/1 00 mL in PEG 400.  
 
How Supplied:   BAY [ADDRESS_605332] ive BAY 43 -9006 tosylate.  
 
BAY 43 -9006 tosylate 200 mg tablets are supplied in bottles of 140 
tablets.  
 
Storage:    Store at controlled room temperature (15ºC – 25ºC). Storage conditions 
should not exceed 25ºC.  
 
Stability:     Stability studies with the 20 0 mg dosage form are ongoing. The current 
shelf life is 24 months when stored at controlled room temperature.  
 
Route (s) of Administration:   Orally  
 
Comprehensive Adverse Events and Potential Risks list (CAEPR)  
for 
Sorafenib (BAY 43 -9006, NSC 724772 ) 
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of reported 
and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by 
[CONTACT_6764]. In addition to the comprehensive list, a su bset, the Specific Protocol Exceptions to 
Expedited Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. 
This subset of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited reporting  
to NCI via AdEERS (except as noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event 
Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  for further 
clarification. Frequency is provided  based on 2157 patients. Below is the CAEPR for sorafenib (BAY 43 -
9006).  
 
 
NCI Version Date 5/23/11  25 NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next to the 
AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple investig ational 
agents and has an AE listed on different SPEERs, use the lower of the grades to determine if 
expedited reporting is required.  
 
Version 2.4, December 21, [ZIP_CODE] 
 
 Adverse Events with Possible  
 Relationship to Sorafenib (BAY 43 -9006)  
 (CTCAE 4.0 Term ) 
[n= 2157]  
   Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER)  
 
(formerly known as ASAEL)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
 Anemia    Anemia (Gr 3)  
 Febrile neutropenia     
CAR DIAC DISORDERS    
  Acute coronary syndrome    
  Left ventricular systolic 
dysfunction    
  Myocardial infarction    
GASTROINTESTINAL DISORDERS    
Abdominal pain     Abdominal pain (Gr 3)  
 Anal mucositis     
 Ascites     
 Constipation    Constipation (Gr 2)  
Diarrhea     Diarrhea (Gr 3)  
 Gastrointestinal hemorrhage2   Gastrointestinal hemorrhage2  
(Gr 3)  
  Gastrointestinal 
perforation3   
 Mucositis oral     
Nausea     Nausea (Gr 3)  
 Rectal mucositis     
 Small intestinal mucositis     
 Vomiting    Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
 Edema limbs     
Fatigue     Fatigue (Gr 3)  
 Fever    Fever (Gr 2)  
 Non-cardiac chest pain     
IMMUNE SYSTEM DISORDERS    
  Anaphylaxis    
INFECTIONS AND INFESTATIONS    
 Infection4    
INVEST IGATIONS    
 Activated partial 
thromboplastin time 
prolonged    Activated partial thromboplastin 
time prolonged (Gr 2)  
Alanine aminotransferase 
increased     Alanine aminotransferase 
increased (Gr 3)  
Alkaline phosphatase 
increased     Alkaline phosphatase i ncreased 
(Gr 3)  
Aspartate aminotransferase 
increased     Aspartate aminotransferase 
increased (Gr 3)  
 
NCI Version Date 5/23/11  26 Blood bilirubin increased     Blood bilirubin increased (Gr 3)  
 Cholesterol high     
Creatinine increased     Creatinine increased (Gr 3)  
 GGT increased     
INR increased     INR increased (Gr 2)  
 Investigations - Other 
(bicarbonate, serum -low)    
Lipase increased     Lipase increased (Gr 3)  
Lymphocyte count decreased     Lymphocyte count decreased  
(Gr 3)  
 Neutrophil count decreased    Neutrophil count dec reased    
(Gr 4)  
Platelet count decreased     Platelet count decreased (Gr 4)  
Serum amylase increased     Serum amylase increased (Gr 3)  
Weight loss     Weight loss (Gr 2)  
White blood cell decreased     White blood cell decreased (Gr 4)  
METABOLISM AND NUT RITION DISORDERS    
Anorexia     Anorexia (Gr 3)  
 Hypercalcemia     
Hyperglycemia     Hyperglycemia (Gr 3)  
 Hyperkalemia    Hyperkalemia (Gr 3)  
 Hypernatremia     
 Hyperuricemia     
Hypoalbuminemia     Hypoalbuminemia (Gr 3)  
Hypocalcemia     Hypocalcemia (G r 3) 
 Hypoglycemia    Hypoglycemia (Gr2)  
 Hypokalemia    Hypokalemia (Gr 3)  
Hyponatremia     Hyponatremia (Gr 3)  
Hypophosphatemia     Hypophosphatemia (Gr 3)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia    Arthralgia (Gr 3)  
 Back pain    Back pain (Gr 3)  
 Bone pain     
 Musculoskeletal and 
connective tissue disorder -  
Other (muscle spasms)     
 Myalgia     
 Pain in extremity  
   Pain in extremity (Gr 3)  
NERVOUS SYSTEM DISORDERS    
 Dizziness     
 Headache    Headache (Gr 3)  
  Intracrania l hemorrhage    
 Peripheral sensory 
neuropathy     
  
 
 Reversible posterior 
leukoencephalopathy 
syndrome    
PSYCHIATRIC DISORDERS    
 Insomnia     
RENAL AND URINARY DISORDERS    
 Acute kidney injury     
 Hematuria     
 Renal hemorrhage     
REPRODUCTIVE SYS TEM AND BREAST DISORDERS    
 
NCI Version Date 5/23/[ADDRESS_605333] hemorrhage     
 Testicular hemorrhage     
 Uterine hemorrhage     
 Vaginal hemorrhage     
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS    
 Bronchopulmonary 
hemorrhage     
 Cough    Cough (Gr 2)  
 Dyspnea    Dyspnea (Gr 3)  
 Epi[INVESTIGATOR_472177] (Gr 2)  
 Dry skin    Dry skin (Gr 2)  
  Erythema multiforme    
Palmar -plantar 
erythrodysesthesia syndrome     Palmar -plantar 
erythrodysesthesia syndrome  
(Gr 3)  
 Pruritus    Pruritus (Gr 3)  
Rash maculo -papular     Rash maculo -papular (Gr 3)  
  Stevens -Johnson  
syndrome    
VASCULAR DISORDERS    
 Hypertension    Hypertension (Gr 3)  
 Thromboembolic event     
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revis ion.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412] .  Your name, the name [CONTACT_6823], the protocol and the agent should 
be included in the e -mail.  
 
2Gastrointestinal hemorrhage includes Anal hemorrhage, Cecal hemorrhage, C olonic hemorrhage, 
Duodenal hemorrhage, Esophageal hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, 
Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra -abdominal hemorrhage, Jejunal hemorrhage, Lower 
gastrointestinal hemorrhage, Oral hemorrhage,  Pancreatic hemorrhage, Rectal hemorrhage, 
Retroperitoneal hemorrhage, and Upper gastrointestinal hemorrhage under the GASTROINTESTINAL 
DISORDERS SOC.  
 
3Gastrointestinal perforation includes Colonic perforation, Duodenal perforation, Esophageal perforation , 
Gastric perforation, Ileal perforation, Jejunal perforation, Rectal perforation, and Small intestinal 
perforation under the GASTROINTESTINAL DISORDERS SOC.  
 
4Includes all 75 infection sites under the INFECTIONS AND INFESTATIONS SOC.  
 
 
 
Also reported on s orafenib (BAY 43 -9006) trials but with the relationship to sorafenib (BAY 43 -
9006) still undetermined:  
 
 
NCI Version Date 5/23/11  28 CARDIAC DISORDERS  - Atrial fibrillation; Atrial flutter; Chest pain - cardiac; Sinus bradycardia; Sinus 
tachycardia; Supraventricular tachycardia  
EAR AN D LABY[CONTACT_33993]  - Tinnitus  
ENDOCRINE DISORDERS  - Hyperthyroidism; Hypothyroidism  
EYE DISORDERS  - Blurred vision; Cataract; Extraocular muscle paresis  
GASTROINTESTINAL DISORDERS  - Abdominal distension; Dyspepsia; Dysphagia; Flatulence; Ileus; 
Pancrea titis; Rectal fistula; Small intestinal obstruction  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Chills; Edema face; Flu like 
symptoms; Pain  
IMMUNE SYSTEM DISORDERS  - Allergic reaction  
INVESTIGATIONS  - Fibrinogen decreased  
METABOLISM AND NUTRITIO N DISORDERS  - Dehydration; Hypermagnesemia; Hypertriglyceridemia; 
Hypomagnesemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Arthritis; Generalized muscle 
weakness  
NERVOUS SYSTEM DISORDERS  - Dysgeusia; Encephalopathy; Ischemia cerebrovascular; Memory  
impairment; Syncope  
PSYCHIATRIC DISORDERS  - Confusion; Depression  
RENAL AND URINARY DISORDERS  - Proteinuria  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Erectile dysfunction  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Hypoxia; Pleural effusion; Pneumo nitis; 
Pneumothorax  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Hyperhidrosis; Purpura; Rash acneiform; Skin and 
subcutaneous tissue disorders - Other (non -life threatening squamous cell carcinoma of skin:  
keratoacanthoma type); Skin hypopi[INVESTIGATOR_472178] R DISORDERS  - Flushing; Hypotension; Vasculitis  
 
Note : Sorafenib (BAY 43 -9006) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by [CONTACT_6767], or the combination may result in events 
never previously associated with either agent.  
 
 
 
 
 
Method of Administration:   Following oral administration, BAY 43 -9006 tosylate’s mean 
relative bioavailability is 38 -49%. When given with a moderate fat 
meal, bioavailability was similar to that in the fasted s tate.  
With a high fat meal, BAY 43 -9006 tosylate’s bioavailability was 
reduced by 29% compared to administration in the fasted state. It is 
recommended that BAY 43 -9006 be taken on an empty stomach (at 
least 1 hour before or 2 hours after eating) and with  at least 250 mL 
of water.  
 
Potential Drug Interactions:   BAY -[ADDRESS_605334] wi th drugs that are metabolized by [CONTACT_941] P450 CYP 
isoenzymes or with drugs that inhibit CYP 3A. Close monitoring 
is recommended for patients taking agents with narrow 
therapeutic indices and metabolized by [CONTACT_4852], such as 
warfarin, phenytoin, quinidine, car bamazepi[INVESTIGATOR_050], phenobarbital, 
 
NCI Version Date 5/23/11  29 cyclosporine, and digoxin.  Additionally, BAY -9006 tosylate is 
97% to 99% protein bound; however, no drug interactions have 
been reported in studies, thus far.  
 
Availability:             BAY 43 -9006 is an investigational agent sup plied to 
investigators by [CONTACT_298839] (DCTD), NCI.  
 
BAY 43 -9006 is provided to the NCI under a Cooperative 
Research and Development Agreement (CRADA) between 
Bayer Corp./Onyx  and the DCTD, NCI (see Section 10.4).  
 
BAY 43 -9006 is provided to the NCI under a Clinical Trials 
Agreement (CTA) between Bayer Corp./Onyx  and the DCTD, 
NCI (see Section 10.4).  
 
Agent Ordering:           NCI-supplied agents may be requested by [CONTACT_9532] (or their authorized designees)  at each participating 
institution.  Pharmaceutical Management Branch (PMB) policy 
requires that the agent be shipped directly to the institution 
where the patient is to be treated.  PMB does not permit the 
transfer of agents between institutions (unless p rior approval 
from PMB is obtained).  Completed Clinical Drug Requests 
(NIH -986) should be submitted to the PMB by [CONTACT_6791] (301) 480 -
4612 or mailed to the Pharmaceutical Management Branch, 
CTEP, DCTD, NCI, 9000 Rockville Pi[INVESTIGATOR_2531], EPN Rm. 7149, 
Bethesda, MD [ZIP_CODE].  
 
Agent Accountability:         The Investigator, or a responsible party designated by [CONTACT_1275], must maintain a careful record of the inventory 
and disposition of all agents received from DCTD using the  
    NCI Drug Accountability Record Form.  See the CTEP web site 
for Policy and Guidelines for Accountability and Storage of 
InvestigationalDrugs( http://ctep.cancer.gov/requisition/storage
.html ). 
 
7.[ADDRESS_605335] description:        Gemcitabine is supplied in Vials: 200 mg white, lyophilized 
powder in a 10 mL size sterile single use vial (No. 7501) (NDC 
0002 -7501 -01) or 1 g white, lyophilized powder in a 50 mL 
size sterile single use vial (No. 7502)  (NDC 0002 -7502 -01). 
store at controlled room temperature (20° to 25°C) (68° to 
77°F). The recommended diluent for reconstitution of 
emcitabine is 0.9% Sodium Chloride Injection without 
preservatives. Due to solubility considerations, the maximum 
 
NCI Version Date 5/23/11  30 concentration for gemcitabine upon reco nstitution is 40 
mg/mL. Reconstitution at concentrations greater than 40 
mg/mL may result in incomplete dissolution, and should be 
avoided.  
Preparation:          To reconstitute, add 5 mL of 0.9% Sodium Chloride Injection 
to the 200 mg vial or 25 mL of 0.9 % Sodium Chloride 
Injection to the 1 g vial. Shake to dissolve. These dilutions each 
yield a gemcitabine concentration of 38 mg/mL which includes 
accounting for the displacement volume of the lyophilized 
powder (0.26 mL for the 200 mg vial or 1.3 mL for th e 1 g 
vial). The total volume upon reconstitution will be 5.26 mL or 
26.3 mL, respectively. Complete withdrawal of the vial 
contents will provide 200 mg or 1 g of gemcitabine, 
respectively. The appropriate amount of drug may be 
administered as prepared or further diluted with 0.9% Sodium 
Chloride Injection to concentrations as low as 0.1 mg/mL.  
Reconstituted gemcitabine is a clear, colorless to light straw -
colored solution. After reconstitution with 0.9% Sodium 
Chloride Injection, the pH of the resulting s olution lies in the 
range of 2.7 to 3.3. The solution should be inspected visually 
for particulate matter and discoloration, prior to administration, 
whenever solution or container permit. If particulate matter or 
discoloration is found, do not administer.   
 
 
Stability:         When prepared as directed, gemcitabine solutions are stable for 
24 hours at controlled room temperature 20° to 25°C (68° to 
77°F) [ See USP]. Discard unused portion. Solutions of 
reconstituted gemcitabine should not be refrigerated, a s 
crystallization may occur.  
The compatibility of gemcitabine with other drugs has not been 
studied. No incompatibilities have been observed with infusion 
bottles or polyvinyl chloride bags and administration sets.  
Unopened vials of gemcitabine are stabl e until the expi[INVESTIGATOR_472179] 20° to 25°C (68° to 77°F) [ See USP].  
Caution should be exercised in handling and preparing 
gemcitabine solutions. The use of gloves is recommended. If 
gemcita bine solution contacts the skin or mucosa, immediately 
wash the skin thoroughly with soap and water or rinse the 
 
NCI Version Date 5/23/11  31 mucosa with copi[INVESTIGATOR_365302]. Although acute dermal 
irritation has not been observed in animal studies, two of three 
rabbits exhibited drug-related systemic toxicities (death, 
hypoactivity, nasal discharge, shallow breathing) due to dermal 
absorption.   
Procedures for proper handling and disposal of anti -cancer 
drugs should be considered. Several guidelines on this subject 
have been publis hed. 1-7  There is no general agreement that all 
of the procedures recommended in the guidelines are necessary 
or appropriate.  
1. Recommendations for the safe handling of parenteral antineoplastic drugs. NIH 
publication No. 83 -2621. US Government Printing Of fice, Washington, DC [ZIP_CODE].  
2. Council on Scientific Affairs: Guidelines for handling parenteral antineoplastics. JAMA 
1985;253:1590.  
3. National Study Commission on Cytotoxic Exposure —Recommendations for handling 
cytotoxic agents, 1987. Available from Louis P  Jeffrey, ScD, Director of Pharmacy 
Services, Rhode Island Hospi[INVESTIGATOR_307], [ADDRESS_605336], Providence, Rhode Island [ZIP_CODE].  
4. Clinical Oncological Society of Australia: Guidelines and recommendations for safe 
handling of antineoplastic agents. Med J Aust 1983;1:4 26.  
5. Jones RB, et al. Safe handling of chemotherapeutic agents: A report from the Mount Sinai 
Medical Center. CA 1983;33(Sept/Oct): 258.  
6. American Society of Hospi[INVESTIGATOR_128579]: Technical assistance bulletin on handling 
cytotoxic drugs in hospi[INVESTIGATOR_600]. Am J  Hosp Pharm 1990;47:1033.  
7. Yodaiken RE, Bennet D, OSHA work -practice guidelines for personnel dealing with 
cytotoxic (antineoplastic) drugs. Am J Hosp Pharm 1988;43:1193 -1204.  
 
Availability:          Gemcitabine is commercially available.  
 
Solution prepar ation :       Please see the package insert for standard preparation 
instructions.  
Route of administration :       Gemcitabine is to be administered as a short intravenous 
infusion over 30 minutes.  
Expected adverse events :         See manufacturer’s package  insert for expected adverse events.  
 
7.[ADDRESS_605337] description :                Capecitabine is provided as biconvex, oblong film -coated tablets 
for oral administration.  Each light peach -colored tablet contains 
150 mg capecitabine and each pe ach-colored tablet contains 500 
mg capecitabine.   
 
Preparation :      Instructions regarding the calculation of the number of tablets to 
achieve the appropriate dosing can be found in Section 4.1.3.  
 
Stability:       Capecitabine tablets should be stored at  room temperature (25°C 
 
NCI Version Date 5/23/11  32 or 77°F).  
 
Availability:      Capecitabine is commercially available.  
 
Route of administration:       Capecitabine is administered by [CONTACT_326372] a day.  Prior studies 
of capecitabine have included administration within 30 minutes 
of food (and safety/efficacy data are based on this schedule), 
therefore, capecitabine will be administered similarly in this 
study.  The tablets should be swallowed with water.  
 
Expected adverse events:      See manufacturer’s package insert for expected adv erse events.  
 
Drug Interactions:      See manufacturer’s package insert for information on drug 
interactions including leucovorin, coumarin derivatives and 
phenytoin
 
NCI Version Date 5/23/11  33 8. CORRELATIVE/SPECIAL STUDIES  
 
Tissue Analysis for MAPK and VEGFR2 Expression   
 
BAY 43 -9006 is a potent inhibitor of wild -type and mutant B -Raf and c -Raf kinase isoforms in 
vitro, with no effects on EGFR, PKC and HER2/neu kinase activities. Activation of Raf initiates 
a signaling cascade that results in MAP kinase phosphorylation(24).   The effe ct of BAY 43 -9006 
on Raf activation and MAP kinase activation in patients receiving the drug has not been well -
studied. Specifically, it is unknown if to what extent 1) activation of Raf kinase - MAP kinase 
signaling axis can predict likelihood of response  2) inhibition of Raf kinase and/or MAP kinase 
activation is necessary for patients to respond to BAY 43 -9006 based therapy;  3) VEGFR2 
activation and subsequent correlates with tumor microvessel density and clinical response; and 4) 
Raf kinase inhibition correlates with phospho -Akt status, a negative upstream regulator of both 
Raf-kinase isoforms. Therefore, we propose to measure MAP kinase activation in pre - and post -
treatment tumor specimens when available.  
 
Pre- and, when available, post -treatment para ffin-embedded tumor tissue specimens will be 
analyzed using monoclonal antibodies specific for activated MAP kinase, c -raf, VEGFR2(25;26), 
MEK, PDGF -R, AKT and PCNA.   To assess potential role of VEGFR2 blockade on 
angiogenesis paraffin -embedded sections w ill be stained for CD31, an endothelial -specific cell 
marker.   
 
Please send paraffin -embedded tumor tissue samples to:  
 
     Scott Tagawa, M.D.  
     Div. of Hematology & Medical Oncology  
     [LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]/Cornell  
     [ADDRESS_605338] 68th Stree t 
     [LOCATION_001], NY 100 65 
     Tel [PHONE_9869]  
     Fax [PHONE_9870]  
 
 
 
 
 
 
NCI Version Date 5/23/[ADDRESS_605339] be done ≤ 4 weeks prior to the start of therapy.   In the event that the 
patient's condition is deteriorating, laboratory evaluations should be repeated within [ADDRESS_605340] cycle 12 who remain on sing le-agent 
sorafenib with stable non -hematologic toxicities of Gr < 1, cycles may be moved to q4 weeks 
with study procedures performed on D1 of each cycle; radiographic evaluation should 
continue every 3 cycles unless clinically indicated sooner regardless o f the length of the 
cycle.  
     
Pre- 
Study   
Wk 
1  
Wk 
2  
Wk 
3  
Wk  
4  
Wk 
5  
Wk 
6  
Wk 
7  
Wk 
8  
Wk 
9  
Wk 
10  
Wk 
11  
Wk 
12  
Off 
Studyc 
 
BAY 43 -9006   
  
A  
A  
A  
A  
A  
A  
A  
A  
A  
A  
A  
A  
 
 
Gemcitabine   
  
B  
B  
  
B  
B  
  
B  
B  
  
B  
B  
  
 
 
Capecitabine   
  
C  
C  
  
C  
C  
  
C  
C  
  
C  
C  
  
 
 
Informed consent   
X  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Demographics   
X  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Medical history   
X  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Concurrent meds   
X  
X---------------------------------------------------------------- --------------------------------- X  
 
 
Physical exam   
X  
X  
  
  
X  
  
  
X  
  
  
X  
  
  
X 
 
Vital signse  
X  
X  
X  
X  
X  
  
  
X  
  
  
X  
  
  
X 
 
Height   
X  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Weight   
X  
X  
  
X  
  
X  
  
X  
  
X  
  
X  
  
X 
 
Performance status   
X  
X  
  
X  
  
X  
  
X  
  
X  
  
X  
  
X 
 
CBC w/diff, plts   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
 
Serum chemistrya  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
 Urine protein/creatinineratiof  
X  
A urine protein/creatinine ratio (UPC ratio) will be done on day [ADDRESS_605341] 9 cycles. After cycle 9, the UPC ratio will be repeated on day 1 of every cycle.   
 
EKG (as indicated)   
X  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Adverse event evaluation   
  
X-------------------------------------------------------------------- ----------------------------- X  
X 
 
 
Tumor measurements   
 
X  
Tumor measurements are repeated  after every 3 cycles.  Documentation (radiologic) 
must be provided for patients removed from study for progressive disease.   
 
Xc 
 
Radiologic evaluation   
X  
Radio logic measurements should be performed after every 3 cycles.   
Xc 
 
B-HCG   
Xb  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
A: BAY 43 -9006 :  200 mg p.o. BID for each  cycle (1 cycle = 21 days). Dose modifications will occur if indicated (see Section 5); BAY 43 -9006 will be a dministered 
day 1 through day 21, and continuously thereafter.  
B: Gemcitabine :  750  mg/m2 IV over 30 minutes. Dose modifications will occur if indicated (see Section 5) ; Gemcitabine will be administered on days 1 and 8 of 
each 21 -day cycle.  
C:       Capec itabine :  415 mg/m2 p.o. twice daily. Dose modifications will occur if indicated (see Section 5); Capecitabine will be administered on days 1 -14 of each 
21-day cycle.  
 
NCI Version Date 5/23/11  35 a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, c reatinine, glucose, LDH, phosphorus, potassium, total protein, SGOT 
[AST], SGPT [ALT], sodium.  
b: Serum pregnancy test (women of childbearing potential).  
c: Off-study evaluation.  Two consecutive measurements taken [ADDRESS_605342] 4ml of a random urine sample in a sterile container (does not need to be 24 -hour sample). Determine protein concentration (mg/dl) and creatinine 
concentration (mg/dl). Divide protein  concentration by [CONTACT_472187].  If spot urine protein/Cr is > 0.2, a 24 hour collection 
for protein and creati nine should be assessed  and the level of proteinuria should be graded per CTCAE.  
 
 
NCI Version Date 5/23/[ADDRESS_605343]  
 
For the purposes of this study, patients should be reevaluated for response every 9 weeks.  In 
addition to a baseline scan, confirmatory scans s hould also be obtained  4 weeks following 
initial documentation of objective response.  
 
10.1.  Definitions  
 
Response and progression will be evaluated in this study using the new international 
criteria proposed by [CONTACT_472188] (RECIST) 
Committee [ JNCI  92(3):205 -216, 2000].  Changes in only the largest diameter 
(unidimensional measurement) of the tumor lesions are used in the RECIST criteria.  
Note:  Lesions are either measurable or non -measurable using the criteria provided 
below.  The term “evaluable” in reference to measurability will not be used because it 
does not provide additional meaning or accuracy.  
 
Final determination of response categorization will be determined by [CONTACT_472189]. See section 10.[ADDRESS_605344] one dimension (longest diameter to be recorded) as >20 mm with 
conventional techniques (CT, MRI, x -ray) or as >[ADDRESS_605345] be recorded in millimeters  (or decimal fractions 
of centimeters).  
 
10.1.2  Non-measurable disease  
All other lesions (or sites of disease), including small lesions (longest 
diameter <20 mm with conventional techniques or <[ADDRESS_605346] 
scan),  are considered non -measurable disease.  Bone lesions, leptomeningeal 
disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, 
inflammatory breast disease, abdominal masses (not followed by [CONTACT_462]), 
and cystic lesions are all non -measurable.  
 
10.1.3  Target lesions  
All measurable lesions up to a maximum of five lesions per organ and 10 
lesions in total, representative of all involved organs, should be identified as 
target lesions  and recorded and measured at baseline.  Target lesions should 
be selected on the basis of their size (lesions with the longest diameter) and 
their suitability for accurate repeated measurements (either by [CONTACT_13458]).  A sum of the longest diameter (LD) for all target  
 
NCI Version Date 5/23/11  37 lesions will be calculated  and reported as the baseline sum LD.  The baseline 
sum LD will be used as reference by [CONTACT_204667].  
 
10.1.4  Non-target lesions  
All other lesions (or sites of disease) should be identified as non-target 
lesions and should al so be recorded at baseline.  Non -target lesions include 
measurable lesions that exceed the maximum numbers per organ or total of all 
involved organs as well as non -measurable lesions.  Measurements of these 
lesions are not required but the presence or abse nce of each should be noted 
throughout follow -up.  
10.2 Guidelines for Evaluation of Measurable Disease  
 
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closely as  possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.  
 
Note:  Tumor lesions that are situated in a previously irradiated area will not be 
considered measurable.   
 
The same method of assessment and the sa me technique should be used to 
characterize each identified and reported lesion at baseline and during follow -up. 
Imaging -based evaluation is preferred to evaluation by [CONTACT_13460]  a treatment.  
 
Clinical lesions.  Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes).  In the case of skin lesions, 
documentation by [CONTACT_6775], including a ruler to estimate t he size of the 
lesion, is recommended.  
 
Chest x -ray.  Lesions on chest x -ray are acceptable as measurable lesions when they 
are clearly defined and surrounded by [CONTACT_6776].  However, CT is preferable.  
 
Conventional CT and MRI.   These techniques should  be performed with cuts of [ADDRESS_605347], 
abdomen, and pelvis.  Head and neck tumors and those of extremi ties usually require 
specific protocols.  
 
Ultrasound (US).   When the primary endpoint of the study is objective response 
evaluation, US should not be used to measure tumor lesions.  It is, however, a 
possible alternative to clinical measurements of superfi cial palpable lymph nodes, 
subcutaneous lesions, and thyroid nodules.  US might also be useful to confirm the 
 
NCI Version Date 5/23/[ADDRESS_605348] normalize for a patient 
to be considered in complete clinical response.  Specific additional criteria for 
standardized usage of prostate -specific antigen (P SA) and CA -125 response in 
support of clinical trials are being developed.  
 
Cytology, Histology.   These techniques can be used to differentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in 
tumor types,  such as germ cell tumors, where known residual benign tumors can 
remain).  
 
The cytological confirmation of the neoplastic origin of any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or 
stable dis ease is mandatory to differentiate between response or stable disease (an 
effusion may be a side effect of the treatment) and progressive disease.  
 
10.3 Response Criteria  
 
10.3.1  Evaluation of target lesions  
 
Complete Response (CR):  Disappearance of all ta rget lesions  
 
Partial Response (PR):   At least a 30% decrease in the sum of the 
longest diameter (LD) of target lesions, taking 
as reference the baseline sum LD  
 
Progressive Disease (PD):   At least a 20% increase in the sum of the LD of 
target lesions, tak ing as reference the smallest 
sum LD recorded since the treatment started or 
the appearance of one or more new lesions  
 
Stable Disease (SD):    Neither sufficient shrinkage to qualify for PR 
nor sufficient increase to qualify for PD, taking 
as reference the  smallest sum LD since the 
treatment started  
 
NCI Version Date 5/23/11  39 10.3.2  Evaluation of non -target lesions  
 
Complete Response (CR):  Disappearance of all non -target lesions and 
normalization of tumor marker level  
 
Incomplete Response/   
Stable Disease (SD):   Persistence of one or  more non -target lesion(s) 
and/or maintenance of tumor marker level above 
the normal limits  
 
Progressive Disease (PD):  Appearance of one or more new lesions and/or 
unequivocal progression of existing non -target 
lesions  
 
Although a clear progression of “non -target” lesions only is exceptional, in 
such circumstances the opi[INVESTIGATOR_13387], and 
the progression status should be confirmed at a later time by [CONTACT_463] 
(or study chair).  
Note:  If tumor markers are initially abo ve the upper normal limit, they must 
normalize for a patient to be considered in complete clinical response.  
 
10.3.[ADDRESS_605349] response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for 
progressive disease the smallest measurements recorded since the treatment 
started).  The patient's best response assignment will depend on the 
achievement of both measurement and confirmation criteria (see s ection 
9.3.1).  
 
NCI Version Date 5/23/11  40   
Target Lesions   
Non-Target Lesions   
New Lesions   
Overall Response  
 
CR  
CR  
No  
CR 
 
CR  
Incomplete 
response/SD   
No  
PR 
 
PR  
Non-PD  
No  
PR 
 
SD  
Non-PD  
No  
SD 
 
PD  
Any  
Yes or No   
PD 
 
Any  
PD  
Yes or No   
PD 
 
Any  
Any  
Yes  
PD 
 
Note : 
 
 Patients with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of disease progression at that time 
should be classified as having “symptomatic deterioration.”  Every effort 
should be made to docum ent the objective progression, even after 
discontinuation of treatment.  
 
 In some circumstances, it may be difficult to distinguish residual disease from 
normal tissue.  When the evaluation of complete response depends on this 
determination, it is recommend ed that the residual lesion be investigated (fine 
needle aspi[INVESTIGATOR_337]/biopsy) before confirming the complete response status.  
 
10.4 Confirmatory Measurement/Duration of Response  
 
10.4.[ADDRESS_605350] once after study entry at a minimum 
interval of  9 weeks (see section 9.3.3).  
 
10.4.2  Duration of overall response  
 
The duration of overall response is measured from the time measurement 
criteria are met for CR or PR (whichever is first recorded) until the first date 
that recurrent or progressive diseas e is objectively documented (taking as 
 
NCI Version Date 5/23/[ADDRESS_605351] measurements recorded since 
the treatment started).  
 
The duration of overall CR is measured from the time measurement criteria 
are first met for CR until the first date t hat recurrent disease is objectively 
documented.  
 
10.4.[ADDRESS_605352] measurements recorded 
since the tre atment started.  
 
10.5 Progression -Free Survival  
 
PFS will be measured from the time of the patient’s initial best response (PR or CR) 
until documented progression.  
 
10.6 Response Review  
 
All objective responses will be evaluated by [CONTACT_472190].  All radiographs 
(such as CT, MRI, bone scan) will be sent to Weill Cornell Medical College for 
central review by [CONTACT_472191]. Electronic format (e.g. on CD) is 
preferred, but hard copi[INVESTIGATOR_444290].  
 
11. REGULATORY AND REPORTING RE QUIREMENTS  
 
Expedited adverse event (AE) reporting for this study is via AdEERS (Adverse Event 
Expedited Reporting System), accessed via the secure CTEP web site 
https:// webapps.ctep.nci.nih.gov/openapps/plsql/gadeers_main$.startup ).  The reporting 
procedures to be followed are presented in the “NCI Guidelines: Expedited Adverse Event 
Reporting Requirements for NCI Investigational Agents” which can be downloaded from the 
CTEP web site (http://ctep.cancer.gov/reporting/adeers.html ).  
 
The descriptions and grading scales found in the revised NCI Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.[ADDRESS_605353] occurred or might occur (Reported Adverse Events and Potential 
Risks) can be found in Se ction 6 (Pharmaceutical Information).  A copy of the CTCAE 
version 4.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov/reporting/ctc.html ).   
 
 
 
 
 
 
NCI Version Date 5/23/11  42  
 
 
11.1 Expedited  Adverse Event R eporting  
(AE; formerly known as Adverse Drug Reaction)  
For this consortium effort, participating institutions will report to the Coordinating 
Center who in turn will report to CTEP.  
 
Expedited reports are submitted to CTEP via the secure AdEERS application  
accessed via the CTEP web site 
(https://webapps.ctep.nci.nih.gov/openapps/plsql/gadeers_main$.startup ).  Those AEs 
that do not require expedited reporting must be repor ted in routine (CDUS) study data 
submissions.   AEs reported through AdEERS must also be reported in routine study 
data submissions.  
11.1.1   
Phase 1 Trials Utilizing an Agent under a CTEP IND:  AdEERS Reporting Requirements 
for Adverse Events That Occur Wit hin [ADDRESS_605354] Dose of the Investigational 
Agent  
 
  
Grade 1   
Grade 2   
Grade 2   
Grade 3   
Grade 3  Grades  
4 & 52 
Unexpected  
and Expected   
Unexpected   
 
Expected  Unexpected  Expected  
Unexpected  
and 
Expected  with  
Hospi[INVESTIGATOR_36397] -
zation  without 
Hospi [INVESTIGATOR_36397]- 
zation  with  
Hospi[INVESTIGATOR_36397] - 
zation  without 
Hospi[INVESTIGATOR_36397] - 
zation  
Unrelated  
Unlikely  Not 
Required  Not 
Required  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  Not 
Required  24-Hour;  
5 Calendar  
Days  
Possible  
Probable  
Definite  Not 
Required  10 Cale ndar 
Days  Not 
Required  24-Hour;  
5 Calendar  
Days  24-Hour;  
5 Calendar  
Days  10 
Calendar  
Days  Not 
Required  24-Hour;  
[ADDRESS_605355] dose of 
treatment with an agent under a CTEP IND require reporting as follows:  
AdEERS 24 -hour notification followed by [CONTACT_432] 5 calendar days for:  
• Grade 3 unexpected events with hospi[INVESTIGATOR_318]  
• Grade 4 unexpected eve nts  
• Grade 5 expected events and unexpected events  
 
2 Although an AdEERS 24 -hour notification is not required for death clearly related to progressive disease, a full report is required 
as outlined in the table.  
December 15, 2004  
Note:   All deaths on stud y require both routine and expedited reporting regardless of 
causality.   Attribution to treatment or other cause must be provided . 
 
• Expedited AE reporting timelines defined:  
➢ “24 hours; 5 calendar days” – The investigator must initially report the AE via 
AdEERS within 24 hours  of learning of the event followed by a complete AdEERS 
report within 5 calendar days  of the initial 24 -hour report.  
➢ “10 calendar days” - A complete AdEERS report on the AE must be submitted within 
10 calendar days  of the investigator l earning of the event.  
 
 
NCI Version Date 5/23/11  43 • Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipi[INVESTIGATOR_6719] (or prolongation of existing hospi[INVESTIGATOR_059]) must be reported 
regardless of attribution  and designation as expected or unexpected  with the 
exception of  any events  identified as protocol 
specific  expedited  adverse  event  reporting  exclusions.  
• Any event that results in persistent or significant disabilities/incapacities, 
congenital anomalies, or birth defects must be reported via AdEERS if the 
even t occurs following treatment with an agent under a CTEP IND.  
• Use the NCI protocol number and the protocol -specific patient ID provided 
during trial registration on all reports.  
 
Phase 2 and 3 Trials Utilizing an Agent under a CTEP IND:  AdEERS Reporting 
Requirements for Adverse Events That Occur Within [ADDRESS_605356] Dose of the 
Investigational Agent  
 
  
Grade 1   
Grade 2   
Grade 2   
Grade 3   
Grade 3  Grades  
4 & 52 Grades  
4 & 52 
Unexpected  
and 
Expected   
Unex -
pected   
 
Expected  Unexpected  Expected  
Unex - 
pected  Expected  with  
Hospi[INVESTIGATOR_36397] -
zation  without 
Hospi[INVESTIGATOR_36397] - 
zation  with  
Hospi[INVESTIGATOR_36397] - 
zation  without 
Hospi[INVESTIGATOR_36397] - 
zation  
Unrelated  
Unlikely  Not 
Required  Not 
Required  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days 10 
Calendar  
Days  
Possible  
Probable  
Definite  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  10 
Calendar  
Days  10 
Calendar  
Days  Not 
Required  24-Hour;  
[ADDRESS_605357] dose 
of treatment with an agent under a CTEP IND require reporting as follows:  
AdEERS 24 -hour notification followed by [CONTACT_432] 5 calendar days for:  
• Grade 4 and Grade 5 unexpected event s  
 AdEERS 10 calendar day report:  
• Grade 3 unexpected events with hospi[INVESTIGATOR_318]  
• Grade 5 expected events  
2 Although an AdEERS 24 -hour notification is not required for death clearly related to progressive disease, a full report is 
required as outlined in the table.  
December 15, 2004  
Note:   All deaths on study require both routine and expedited reporting regardless of 
causality.   Attribution to treatment or other cause must be provided . 
 
• Expedited AE reporting timelines de fined:  
➢ “24 hours; 5 calendar days” – The investigator must initially report the AE via 
AdEERS within 24 hours  of learning of the event followed by a complete AdEERS 
report within 5 calendar days  of the initial 24 -hour report.  
➢ “10 calendar days” - A complet e AdEERS report on the AE must be submitted within 
10 calendar days  of the investigator learning of the event.  
 
• Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipi[INVESTIGATOR_6719] (or prolongation of existing hospi[INVESTIGATOR_059]) must be reported regardless 
of attribution  and designation as expected or unexpected  with the exception of  any 
events  identified as protocol -specific  expedited  adverse  event  reporting  exclusions.  
 
NCI Version Date 5/23/11  44 • Any event that results in persistent or significant disabilities/inc apacities, 
congenital anomalies, or birth defects must be reported via AdEERS if the event occurs 
following treatment with an agent under a CTEP IND.  
• Use the NCI protocol number and the protocol -specific patient ID provided 
during trial registration on all  reports.  
11.1.2  Expedited Adverse Event Reporting Exclusions.  
N/A  
 
11.1.3  Secondary AML/MDS  
 
Investigators are required to report cases of secondary AML/MDS occurring 
on or following treatment on NCI -sponsored chemotherapy protocols using 
the NCI/CTEP Secondary  AML/MDS Report Form.   This form can be 
downloaded from the CTEP web site 
(http://ctep.cancer.gov/reporting/index.html ).  Second malignancies and non -
AML/MDS secondary malignancies ( e.g., endomet rial cancer in a breast 
cancer patient receiving tamoxifen) should NOT be reported via AdEERS but 
should be submitted as part of the study results via routine CDUS reporting.  
 
11.2 Data Reporting  
 
This study will be monitored by [CONTACT_472192] (CDUS) version 
3.0.  Cumulative CDUS data will be submitted quarterly to CTEP by [CONTACT_471].  Reports are due January 31, April 30, July 31, and October 31.   Instructions 
for submitting data using the CDUS can be found on the CTEP web site 
(http://ctep.cancer.gov/reporting/cdus.html ). 
 
11.[ADDRESS_605358] page and the signature [CONTACT_472196] a one page registration form.  These documents should be faxed 
Monday to Friday from 9:00 AM to 5:00 PM.  The following information will be 
obtained or assigned at that time:  
Protocol Number  
Investigator Identification  
Patient Identification (grant number, institution number, sequence number)  
 
Data Collection Forms: All data forms must be sent to the Coordinating Office on a 
quarterly basis (every 3 months).  
Responsibility of the Protocol Chair  
• The Protocol Chair will  be the single liaison with the CTEP Protocol and 
 
NCI Version Date 5/23/11  45 Information Office (PIO).  The Protocol Chair is responsible for the coordination, 
development, submission, and approval of the protocol as well as its subsequent 
amendments.  The protocol must not be rewri tten or modified by [CONTACT_472193].  There will be only one version of the protocol, and each 
participating institution will use that document.  The Protocol Chair is responsible 
for assuring that all participating institutions are us ing the correct version of the 
protocol.  
• The Protocol Chair is responsible for the overall conduct of the study at all 
participating institutions and for monitoring its progress.  All reporting 
requirements to CTEP are the responsibility of the Protocol Ch air.  
• The Protocol Chair is responsible for the timely review of Adverse Events 
(AE) to assure safety of the patients.  
• The Protocol Chair will be responsible for the review of and timely 
submission of data for study analysis.  
 
Responsibilities of the Coord inating Center  
• Each participating institution will have an appropriate assurance on file 
with the Office for Human Research Protection (OHRP), NIH.   The Coordinating 
Center is responsible for assuring that each participating institution has an OHRP 
assuran ce and must maintain copi[INVESTIGATOR_36419].  
•  Prior to the activation of the protocol at each participating institution, an 
OHRP form 310 (documentation of IRB approval) must be submitted to the CTEP 
PIO. 
• The Coordinating Cen ter is responsible for central patient registration.  
The Coordinating Center is responsible for assuring that IRB approval has been 
obtained at each participating site prior to the first patient registration from that 
site. 
• The Coordinating Center is resp onsible for the preparation of all submitted 
data for review by [CONTACT_36476].  
• The Coordinating Center will maintain documentation of AE reports.  
There are two options for AE reporting: (1) participating institutions may report 
directly to CTEP with a copy to the Coordinating Center, or (2) participating  
institutions report to the Coordinating Center who in turn report to CTEP.  The 
Coordinating Center will submit AE reports to the Protocol Chair for timely 
review.  
• Audits may be accomplished in one o f two ways:  (1) source documents 
and research records for selected patients are brought from participating sites to 
the Coordinating Center for audit, or (2) selected patient records may be audited 
on-site at participating sites.  If the NCI chooses to ha ve an audit at the 
Coordinating Center, then the Coordinating Center is responsible for having all 
source documents, research records, all IRB approval documents, NCI Drug 
Accountability Record forms, patient registration lists, response assessments 
scans,  x-rays, etc. available for the audit.  
Agent Ordering  
• Except in very unusual circumstances, each participating institution will 
 
NCI Version Date 5/23/[ADDRESS_605359] Language to Be Incorporated into All Protocols Involving Agent(s) 
Covered by a Clinical Trials Agreement (CTA) or a Cooperative Research and 
Development Agreement (CRADA), hereinafter referred to as Collaborative 
Agreement:  
 
The agent(s), supplied by [CONTACT_472], DCTD, NCI, used in this protocol is/are provided to 
the NCI under a Collaborative Agreement (CRADA, CTA) between the 
Pharmaceut ical Company(ies) [hereinafter referred to as Collaborator(s)] and the NCI 
Division of Cancer Treatment and Diagnosis.  Therefore, the following 
obligations/guidelines, in addition to the provisions in the Intellectual Property 
Option to Collaborator conta ined within the terms of award, apply to the use of    
Agent(s) in this study:  
 
1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor 
can Agent(s) be transferred or licensed to any party not participating in the clinical 
study.   Collaborator(s) data for Agent(s) are confidential and proprietary to 
Collaborator(s) and shall be maintained as such by [CONTACT_473].  The protocol 
documents for studies utilizing investigational agents contain confidential 
information and should n ot be shared or distributed without the permission of the 
NCI.  If a copy of this protocol is requested by a patient participating on the study 
or patient’s family member, the individual should sign a confidentiality 
agreement.  A suitable model agreement can be downloaded from: 
http://ctep.cancer.gov . 
 
2. For a clinical protocol where there is an investigational Agent used in 
combination with (an)other investigational Agent(s), each the subject of different  
collabor ative agreements, the access to and use of data by [CONTACT_472194] (data pertaining to such combination use shall hereinafter be 
referred to as "Multi -Party Data”.):  
 
a. NCI must provide all Collaborators with prior written notice reg arding the 
existence and nature of any agreements governing their collaboration with 
NIH, the design of the proposed combination protocol, and the existence of 
any obligations that would tend to restrict NCI's participation in the proposed 
combination prot ocol.  
 
b. Each Collaborator shall agree to permit use of the Multi -Party Data from the 
clinical trial by [CONTACT_170731], obtain regulatory approval, or 
commercialize its own  investigational agent.  
 
NCI Version Date 5/23/[ADDRESS_605360] agree in writing prior to the commencement of the trials that it will use 
the Multi -Party Data solely for development, regulatory approval, and  
commercialization of its own investigational agent.  
 
 
3. Clinical Trial Data and Results and Raw Data developed under a collaborative 
agreement will be made available exclusively to Collaborator(s), the NCI, and the 
FDA, as appropriate.  All data made ava ilable will comply with HIPAA 
regulations.  
 
4. When a Collaborator wishes to initiate a data request, the request should first be 
sent to the NCI, who will then notify the appropriate investigators (Group Chair 
for Cooperative Group studies, or PI [INVESTIGATOR_435949] r studies) of Collaborator's wish to 
contact [CONTACT_476].  
 
5. Any data provided to Collaborator(s) for phase [ADDRESS_605361] be in accordance 
with the guidelines and policies of the responsible Data Monitoring Committee 
(DMC), if there is a DMC for this clinical t rial. 
 
6. Any manuscripts reporting the results of this clinical trial must be provided to 
CTEP for immediate delivery to Collaborator(s) for advisory review and comment 
prior to submission for publication.  Collaborator(s) will have [ADDRESS_605362] that 
publication be delayed for up to an additional 30 days in order to ensure that 
Collaborator’s confidential and proprietary data, in addition to Collaborator(s)’s 
intellectual propert y rights, are protected.  Copi[INVESTIGATOR_6723](s) for courtesy review as soon as possible 
and preferably at least three (3) days prior to submission, but in any case, prior to 
presentation at the meeti ng or publication in the proceedings.  Press releases and 
other media presentations must also be forwarded to CTEP prior to release.  
Copi[INVESTIGATOR_352], abstract, and/or press release/ media presentation 
should be sent to:  
 
Regulatory Affairs Branch , CTEP, DCTD, NCI  
    [ADDRESS_605363]  
Rockville, MD  [ZIP_CODE]  
FAX 301 -402-1584  
   E-mail: [EMAIL_5897]  
 
 The Regulatory Affairs Branch will then distribute them to Collaborator( s).  No 
publication, manuscript or other form of public disclosure shall contain any of 
Collaborator’s confidential/proprietary information.  
 
12. STATISTICAL CONSIDERATIONS  
 
NCI Version Date 5/23/11  48  
12.1 Study Design/Endpoints  
 
The study is a prospective, non -randomized, multi -institutional phase II trial with 
objective response as the major endpoint.  Recent trials using gemcitabine in 
combination with [ADDRESS_605364] demonstrated response rates in 
the range of 15 - 21%(20;27) .  The trial is designed to effectively discriminate between 
true response rates of no more than 10% and at least 30%.  The maximum trial size 
will be set at [ADDRESS_605365] 6 r esponses (at least 17%) were 
observed among the 35 evaluable patients, this regimen would be considered worthy 
of further testing in this disease.  If no more than 1 response (no more than 8%) were 
observed among the initial [ADDRESS_605366] 90% power to detect a true response rate 
of at least 30%.  It yields at least .90 probability of a negative result if the true 
response rate is no more than 10%, with at least .65 probab ility of early negative 
stoppi[INVESTIGATOR_007].   
 
12.2 Sample Size/Accrual Rate  
 
The maximum trial size will be set at [ADDRESS_605367] ing in this disease.  If no more than 1 response were observed 
among the initial 12 patients, the study would be terminated early and declared 
negative.   
 
An estimated accrual of 3 -4 patients per month is expected with a goal to complete 
the trial within one year  
 
12.3 Stratification Factors  
 
N/A 
 
12.4 Analysis of Secondary Endpoints  
 
Progression free survival and overall survival will be assessed.  Because of the 
heterogeneity in outcome of patients with advanced renal cell carcinoma, assessment 
of surviv al will be limited.  Nevertheless, median survival for this group of patients 
has historically been < 12 months.  Improvement over that level will be encouraging.  
Likewise, PFS > [ADDRESS_605368] -treatment paraffin -embedded tumor tissue specimens 
will be analyzed using monoclonal antibodies specific for total and activated MAP 
 
NCI Version Date 5/23/[ADDRESS_605369] be assessed 
for response to treatment, even if there are major protocol treatment deviations 
or if they are ineligible.  Each patient will be assigned one of the following 
categories:  1) complete response, 2) partial response, 3) stable disease, 4) 
progressive disease, 5) early death from malignant disease, 6) early death from 
toxicity, 7) early death because of other cause, or 9) unknown (not assessable, 
insufficient data).  [Note:  By [CONTACT_480], category 9 usually 
designates the “unknown” status of any type of data in a clinical database.]  
 
All of the patients who met the eligibility criter ia (with the possible exception 
of those who received no study medication) should be included in the main 
analysis of the response rate.  Patients in response categories 4 -9 should be 
considered as failing to respond to treatment (disease progression).  Th us, an 
incorrect treatment schedule or drug administration does not result in 
exclusion from the analysis of the response rate.  Precise definitions for 
categories 4 -9 will be protocol specific.  
 
 
NCI Version Date 5/23/[ADDRESS_605370] E et al. Cancer statistics, 
2004. CA Cancer J.Clin.  2004;54:8 -29. 
 2.  Vogelzang NJ, Stadler WM. Kidney cancer. Lancet  1998;352:1691 -6. 
 3.  Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T et al. Prospective 
randomized tr ial of interferon alfa -2a plus vinblastine versus vinblastine alone in patients 
with advanced renal cell cancer. J.Clin.Oncol  1999;17:2859 -67. 
 4.  Interferon -alpha and survival in metastatic renal carcinoma: early results of a randomised 
controlled trial.  Medical Research Council Renal Cancer Collaborators. Lancet  
1999;353:14 -7. 
 5.  Campbell SL, Khosravi -Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of 
Ras signaling. Oncogene  1998;17:1395 -413. 
 6.  Chong H, Vikis HG, Guan KL. Mechanisms of re gulating the Raf kinase family. Cell 
Signal.  2003;15:463 -9. 
 7.  Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF 
gene in human cancer. Nature  2002;417:[ADDRESS_605371] CA. Raf proteins and cancer: B -Raf is identified as a mutational 
target. Biochim.Biophys.Acta  2003;1653:25 -40. 
 9.  Pollock PM, Meltzer PS. A genome -based strategy uncovers frequent BRAF mutations in 
melanoma. Cancer Cell  2002;2:[ADDRESS_605372].  2003;95:484 -6. 
 11.  Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H et al. 
Mutations of the  BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. 
Gut 2003;52:[ADDRESS_605373].  2003;95:[ADDRESS_605374] for tumour angiogenesis factors. Nat.Rev.Cancer  
2002;2:795 -803. 
 
 
 
NCI Version Date 5/23/[ADDRESS_605375]  
2003;111:1287 -95. 
 15.  Apperley JF, Gardembas M, Melo JV, Russell -Jones R, Bain BJ, Baxter EJ et al. Response 
to imatinib mesylate in patients with chronic myeloproliferative diseases with 
rearrangements of the platelet -derived growth factor recept or beta. N.Engl.J.Med.  
2002;347:481 -7. 
 16.  Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute 
myeloid leukemia. Cancer Cell  2002;1:413 -5. 
 17.  Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase 
activity: a novel molecular approach to the treatment of KIT -positive malignancies. J.Clin 
Oncol  2002;20:[ADDRESS_605376] apoptotic stimuli. Science  2003;301:94 -6. 
 19.  Milowsky MI, Nanus DM. Chemotherapeutic strategies for renal cell carcinoma. Urol 
Clin.North Am  2003;30:601 -9, x. 
 20.  J.S.Waters, C.Moss, S.Hackett, M.James, L.Pyle, R.A'Hern, M.Gore, and T.Eisen. A phase 
II trial of gemcitabine (GE M) plus capecitabine (CAPE) in patients with metastatic renal 
cell carcinoma (MRCC). Proc Annu Meet Am Soc Clin Oncol 1549, 2003 (abstr).  
 21.  Rini BI, Vogelzang NJ, Dumas MC, Wade JL, III, Taber DA, Stadler WM. Phase II trial of 
weekly intravenous gemcit abine with continuous infusion fluorouracil in patients with 
metastatic renal cell cancer. J.Clin Oncol  2000;18:2419 -26. 
 22.  Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T et al. Prognostic factors for 
survival with gemcitabine plus 5 -fluoroura cil based regimens for metastatic renal cancer. 
J.Urol  2003;170:1141 -5. 
 23.  L.L.Siu, C.H.Takimoto, A.Awada, M.J.Moore, M.Pi[INVESTIGATOR_94899], M.Poulin -Costello, C.Lathia, 
and O.Petrenciuc. A phase I/II trial of BAY 43 -9006 and gemcitabine in advanced solid 
tumors an d in advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol 3059, 2004 
(abstr).  
 24.  Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL et al. Signal 
transduction mediated by [CONTACT_147874]/Raf/MEK/ERK pathway from cytokine receptors to 
transcription factors: potential targeting for therapeutic intervention. Leukemia  
2003;17:1263 -93. 
 25.  Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. Activation of mitogen -
activated protein kinase associated with prostate cancer progression.  Cancer Res  
1999;59:279 -84. 
 
NCI Version Date 5/23/11  52  26.  Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by [CONTACT_472195] -specific antibodies to MEK and ERK: potential for pharmacodynamic 
monitoring of signal transduction inhibitors. Cytometry  2001;46:72 -8. 
 27.  W.M.Stadler, S.Halabi, M.S.Ernstoff, R.Barrier, E.Davila, J.Pi[INVESTIGATOR_361], and E.J.Small. A phase 
II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell 
cancer (mRCC): A report of Cancer and Leukemia Group B #[ZIP_CODE] . Proc Annu Meet Am 
Soc Clin Oncol 4515, 2004 (abstr).  
 
 
NCI Version Date 5/23/11     APPENDIX A  
 
 
Performance Status Criteria  
 
 
ECOG Performance Status Scale  
  
Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able 
to carry on al l pre-disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but amb ulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work).  80 Normal activity with effort; some 
signs or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the time.  
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  [ADDRESS_605377] of his/her 
needs.  
50 Requires consi derable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospi[INVESTIGATOR_373].  Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair.  20 Very sick, hospi[INVESTIGATOR_374]. 
Death not imminent.  
10 Moribund, fata l processes 
progressing rapi[INVESTIGATOR_375].  
5 Dead.  0 Dead.  
 
 
 
 
 
 
 
 
 
 
 
A-1
NCI Version Date 5/23/11     APPENDIX B  
 
Patient Medication Log  
 
Patient’s Name ________________________                 Cycle # _________  
Day of Cycle  Date  Capecitabine  
 
Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:_ __(PM)   ____# pi[INVESTIGATOR_472181] 43 -9006  
 
Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
 
1 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
2 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
3 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi [INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
4 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
5 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
6 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ___ _# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
7 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
8 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_3353] t aken  
Time ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
9 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
10 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
11 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
12 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
13 __/__ /__ Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
14 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_472182] ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
15 __/__/__   Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
16 __/__/__   Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
17 __/__/__   Time ___: ___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
18 __/__/__   Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
19 __/__/__   Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
20 __/__/__   Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
21 __/__/__   Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
A-2 
 
NCI Version Date 5/23/11     APPENDIX C  
 
Patient Medication Log – For subjects who remain on single -agent sorafenib  
A-3 
 
 
 Day of 
Cycle  Date  BAY 43 -9006  
 
Time ___:___(AM)   ____# pi[INVESTIGATOR_472180] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
 
1 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
2 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___ (PM)   ____# pi[INVESTIGATOR_38947]  
3 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
4 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
5 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:_ __(PM)   ____# pi[INVESTIGATOR_38947]  
6 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
7 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
8 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___ :___(PM)   ____# pi[INVESTIGATOR_38947]  
9 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
10 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
11 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183]  ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
12 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
13 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
14 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472182] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
15 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
16 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
17 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
18 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
19 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
20 __/__/__  Time ___:___(AM)   ____# p ills taken Time ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
21 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
22 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
23 __/__/__  Time ___:___(AM)   __ __# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
24 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
25 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
26 __/__/__  Time ___:___(AM)    ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
27 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  
28 __/__/__  Time ___:___(AM)   ____# pi[INVESTIGATOR_472183] ___:___(PM)   ____# pi[INVESTIGATOR_38947]  